


# IMPACT OF INCOMPLETE METABOLISM ON HEALTH



Editor:  
**Rajesh Kumar**

**Bentham Books**

# **Impact of Incomplete Metabolism on Health**

Edited by

**Rajesh Kumar**

*Maharaja Agrasen School of Pharmacy*

*Maharaja Agrasen University*

*Solan, Himachal Pradesh, India*

## **Impact of Incomplete Metabolism on Health**

Editor: Rajesh Kumar

ISBN (Online): 979-8-89881-249-2

ISBN (Print): 979-8-89881-250-8

ISBN (Paperback): 979-8-89881-251-5

© 2025, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore, in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2025.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the



need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Pte. Ltd.**

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: [subscriptions@benthamscience.net](mailto:subscriptions@benthamscience.net)



## CONTENTS

|                                                                               |     |
|-------------------------------------------------------------------------------|-----|
| <b>FOREWORD</b> .....                                                         | i   |
| <b>PREFACE</b> .....                                                          | ii  |
| <b>LIST OF CONTRIBUTORS</b> .....                                             | iii |
| <b>CHAPTER 1 INSIGHTS INTO METABOLISM</b> .....                               | 1   |
| <i>Sunil Dutt, Ankit Awasthi, Rajesh Kumar and Ashutosh Kumar</i>             |     |
| <b>INTRODUCTION</b> .....                                                     | 1   |
| <b>DRUG METABOLISM PATHWAYS</b> .....                                         | 3   |
| Linear Pathway .....                                                          | 3   |
| Cyclic Pathways .....                                                         | 5   |
| Branched Pathways .....                                                       | 5   |
| IMPORTANT BIOSYNTHETIC ROUTES FOR AMINO ACIDS THAT ARE NOT<br>ESSENTIAL ..... | 7   |
| Alanine Biosynthesis .....                                                    | 7   |
| Tyrosine and Phenylalanine Synthesis .....                                    | 7   |
| Fatty Acid Metabolism .....                                                   | 8   |
| Pentose Phosphate Pathway (PPP) .....                                         | 8   |
| Purine Metabolism .....                                                       | 8   |
| Glycolysis and Gluconeogenesis .....                                          | 9   |
| ENERGY IN METABOLISM .....                                                    | 10  |
| ENZYMES IN METABOLISM .....                                                   | 13  |
| REGULATION IN METABOLISM .....                                                | 17  |
| Hormonal Regulation .....                                                     | 17  |
| NUTRIENT AVAILABILITY .....                                                   | 18  |
| Fed State: Glucose Abundance and Metabolic Shifts .....                       | 18  |
| Fasting State: Metabolic Adaptations and Energy Mobilization .....            | 19  |
| Protein Metabolism: Adaptation and Conservation .....                         | 20  |
| Hormonal and Cellular Signaling: Integration and Regulation .....             | 20  |
| GENETIC AND EPIGENETIC REGULATION .....                                       | 21  |
| Genetic Regulation in Metabolism .....                                        | 21  |
| Transcription Factors .....                                                   | 21  |
| Gene Promoters and Enhancers .....                                            | 21  |
| Nutrient-Sensitive Pathways .....                                             | 22  |
| EPIGENETIC REGULATION IN METABOLISM .....                                     | 22  |
| DNA Methylation .....                                                         | 22  |
| Histone Modification .....                                                    | 22  |
| Non-Coding RNAs .....                                                         | 23  |
| Environmental Influences .....                                                | 23  |
| INTERACTION BETWEEN GENETIC AND EPIGENETIC REGULATION .....                   | 23  |
| CONCLUSION .....                                                              | 24  |
| REFERENCES .....                                                              | 25  |
| <b>CHAPTER 2 UNDERSTANDING INCOMPLETE METABOLISM</b> .....                    | 35  |
| <i>Anjna Sharma, Hitesh Chopra, Sunil Dutt and Rajesh Kumar</i>               |     |
| <b>INTRODUCTION</b> .....                                                     | 35  |
| <b>COMPLETE VS. INCOMPLETE DRUG METABOLISM</b> .....                          | 36  |
| <b>CHARACTERISTICS OF INCOMPLETE METABOLISM</b> .....                         | 36  |
| Alcohol Metabolism and Acetaldehyde Accumulation .....                        | 37  |
| Phenylketonuria (PKU) .....                                                   | 38  |

|                                                                                     |    |
|-------------------------------------------------------------------------------------|----|
| Maple Syrup Urine Disease (MSUD) .....                                              | 38 |
| Galactosemia .....                                                                  | 39 |
| <b>PHYSIOLOGICAL EFFECTS OF INCOMPLETE METABOLISM</b> .....                         | 40 |
| Accumulation of Intermediate Metabolites .....                                      | 40 |
| Energy Production Inefficiencies .....                                              | 40 |
| Cellular Stress and Damage .....                                                    | 41 |
| <b>INCOMPLETE METABOLISM DIAGNOSIS AND DETECTION</b> .....                          | 42 |
| <b>MANAGEMENT AND TREATMENT STRATEGIES</b> .....                                    | 43 |
| Dietary Strategies .....                                                            | 43 |
| Therapy Involving Enzyme Replacement .....                                          | 44 |
| <b>PUBLIC HEALTH IMPLICATIONS</b> .....                                             | 46 |
| <b>CONCLUSION</b> .....                                                             | 48 |
| <b>REFERENCES</b> .....                                                             | 48 |
| <b>CHAPTER 3 METABOLIC PATHWAYS AND INTERMEDIATES</b> .....                         | 55 |
| <i>Jyoti, Saurav Kumar, Yogendra Singh and Sunil Dutt</i>                           |    |
| <b>INTRODUCTION</b> .....                                                           | 55 |
| <b>METABOLIC PATHWAY</b> .....                                                      | 57 |
| Catabolism .....                                                                    | 58 |
| Anabolism .....                                                                     | 58 |
| Gluconeogenesis, Fatty Acid Synthesis, Protein Synthesis, Amphibolic Pathways ..... | 59 |
| Significance of Metabolic Pathways .....                                            | 60 |
| Cellular Metabolism .....                                                           | 61 |
| Network Metabolism .....                                                            | 62 |
| <b>METABOLIC INTERMEDIATES AND THEIR ROLES</b> .....                                | 63 |
| Pentose Phosphate Pathway .....                                                     | 66 |
| Fatty Acid and Amino Acid Metabolism .....                                          | 67 |
| <b>INTEGRATION AND REGULATION OF METABOLIC PATHWAYS</b> .....                       | 69 |
| Integration of Metabolic Pathways .....                                             | 69 |
| <b>METABOLIC INTERMEDIATES</b> .....                                                | 70 |
| Types of Metabolic Intermediates .....                                              | 70 |
| Carbohydrate Metabolism Intermediates .....                                         | 71 |
| Lipid Metabolism Intermediates .....                                                | 72 |
| Amino Acid Metabolism Intermediates and Nucleotide Metabolism Intermediates .....   | 72 |
| Citric acid Cycle (TCA Cycle) Intermediates .....                                   | 73 |
| <b>ROLE OF INTERMEDIATES IN METABOLIC PATHWAYS</b> .....                            | 73 |
| Glucose-6-Phosphate as a Metabolic Intermediate .....                               | 74 |
| Pyruvate as a Metabolic Intermediate .....                                          | 75 |
| <b>MECHANISMS OF PYRUVATE IN VARIOUS BIOLOGICAL ACTIVITIES</b> .....                | 75 |
| Link to the Citric Acid Cycle (TCA Cycle) .....                                     | 75 |
| Alpha-Ketoglutarate as a Metabolic Intermediate .....                               | 77 |
| <b>ROLES OF OXALOACETATE IN VARIOUS BIOLOGICAL ACTIVITIES</b> .....                 | 79 |
| Role in the TCA Cycle .....                                                         | 79 |
| <b>CONCLUSION</b> .....                                                             | 82 |
| <b>REFERENCES</b> .....                                                             | 82 |
| <b>CHAPTER 4 HEALTH IMPLICATIONS OF INCOMPLETE METABOLISM</b> .....                 | 90 |
| <i>Pankaj Kalia, Swati Pundir, Ashish Sharma, Rajesh Kumar and Amit Aggarwal</i>    |    |
| <b>INTRODUCTION</b> .....                                                           | 91 |
| Metabolic Pathways and Disorders .....                                              | 92 |
| Metabolic Toxicity and Drug Accumulation .....                                      | 93 |
| Incomplete Metabolism and Related Issues .....                                      | 95 |

|                                                                                                 |     |
|-------------------------------------------------------------------------------------------------|-----|
| Mechanisms Leading to Metabolic Toxicity and Drug Accumulation .....                            | 95  |
| Clinical Implications .....                                                                     | 96  |
| Nutrient Metabolism, Vitamin Deficiencies, and Mineral Imbalance in Incomplete Metabolism ..... | 96  |
| Incomplete Metabolism of Nutrients .....                                                        | 96  |
| Vitamin Deficiencies in Incomplete Metabolism .....                                             | 97  |
| Mineral Imbalance in Incomplete Metabolism .....                                                | 97  |
| Incomplete Metabolism of Lipids During Fatty Liver Diseases .....                               | 98  |
| Amino Acid Metabolism and Maple Syrup Urine Disease .....                                       | 99  |
| Incomplete Metabolism of Amino Acids in Maple Syrup Urine Disease .....                         | 99  |
| Urea Cycle Disorder and Maple Syrup Urine Disease .....                                         | 100 |
| Incomplete Metabolism of Carbohydrate in Glycogen Disorder Leads to Diabetes Mellitus .....     | 101 |
| Mitochondrial Disorder and Oxidative Stress .....                                               | 102 |
| Incomplete Metabolism of Drugs Due to Mitochondrial Disorder .....                              | 102 |
| Incomplete Metabolism of Nutrients due to Mitochondrial Disorder .....                          | 103 |
| Repercussions on Carbohydrate Metabolism .....                                                  | 103 |
| Effect on Fatty Acid Oxidation .....                                                            | 104 |
| Significance of Amino Acid Catabolism .....                                                     | 104 |
| Incomplete Metabolism of Vitamins Due to Mitochondrial Disorder .....                           | 104 |
| Incomplete Metabolism of Drugs Due to Oxidative Stress .....                                    | 105 |
| Incomplete Metabolism of Nutrients Due to Oxidative Stress .....                                | 107 |
| Incomplete Metabolism of Vitamins Due to Oxidative Stress .....                                 | 108 |
| Enzyme Replacement and Gene Therapy .....                                                       | 110 |
| Enzyme Replacement in Incomplete Metabolism .....                                               | 110 |
| Gene Therapy in Incomplete Metabolism .....                                                     | 112 |
| Management and Treatment .....                                                                  | 114 |
| Pharmacogenomics and Personalized Medicine .....                                                | 114 |
| Enzyme Induction or Inhibition .....                                                            | 114 |
| Nanotechnology and Drug Delivery Systems .....                                                  | 115 |
| Prodrug Design .....                                                                            | 115 |
| Nutrient and Vitamin Formulation Adjustments .....                                              | 116 |
| Co-Factor Supplementation .....                                                                 | 116 |
| Metabolic Pathway Modulation .....                                                              | 116 |
| Biodegradable Nanomaterials for Targeted Metabolism .....                                       | 116 |
| <b>CONCLUSION</b> .....                                                                         | 117 |
| <b>REFERENCES</b> .....                                                                         | 118 |
| <b>CHAPTER 5 CASE STUDIES AND PATIENT STORIES</b> .....                                         | 125 |
| <i>Devinder Kumar, Brijesh Kumar, Rajesh Kumar and Pratistha Singh</i>                          |     |
| <b>INTRODUCTION</b> .....                                                                       | 126 |
| <b>ROLE OF FOOD INTERACTION IN INCOMPLETE METABOLISM</b> .....                                  | 127 |
| Case Study 1: Lactose 2 and Dairy Products .....                                                | 128 |
| Patient Story: Maria's Struggle with Lactose Intolerance .....                                  | 128 |
| Case Study 2: Grapefruit Juice and Medication Metabolism .....                                  | 130 |
| Patient Story: John's Experience with Statins and Grapefruit Juice .....                        | 130 |
| Case Study 3: Vitamin B12 Deficiency and Dietary Choices .....                                  | 130 |
| Patient Story: Linda's Battle with Vitamin B12 Deficiency .....                                 | 130 |
| Case Study 4: Vitamin D Deficiency and Calcium Absorption .....                                 | 131 |
| Patient Story: Anna's Struggle with Vitamin D Deficiency .....                                  | 131 |
| Case Study 5: Hyperuricemia and Purine-Rich Foods .....                                         | 131 |
| Patient Story: George's Battle with Gout .....                                                  | 132 |

|                                                                                          |     |
|------------------------------------------------------------------------------------------|-----|
| <b>DRUG INTERACTIONS WITH REFERENCE TO INCOMPLETE METABOLISM</b>                         | 132 |
| Case Study 1: Warfarin and Vitamin K-Rich Foods                                          | 133 |
| Patient Story: Margaret's Warfarin Therapy Complications                                 | 133 |
| Case Study 2: Antiepileptic Drugs and Oral Contraceptives                                | 133 |
| Patient Story: Lisa's Unplanned Pregnancy                                                | 134 |
| Case Study 3: Digoxin and Amiodarone                                                     | 134 |
| Patient Story: Michael's Digoxin Toxicity                                                | 134 |
| Case Study 4: Fluoroquinolones and Theophylline                                          | 134 |
| Patient Story: Tom's Theophylline Overdose                                               | 134 |
| Case Study 5: Rifampin and Oral Anticoagulants                                           | 135 |
| Patient Story: Alan's Stroke Risk                                                        | 135 |
| <b>DISEASE-INDUCED INCOMPLETE METABOLISM</b>                                             | 135 |
| Case Study 1: Liver Cirrhosis and Drug Metabolism                                        | 136 |
| Patient Story: Sarah's Sedative Overdose                                                 | 137 |
| Case Study 2: Chronic Kidney Disease and Drug Clearance                                  | 137 |
| Patient Story: Michael's Digoxin Toxicity                                                | 137 |
| Case Study 3: Congestive Heart Failure and Hepatic Congestion                            | 137 |
| Patient Story: Alice's Warfarin Sensitivity                                              | 137 |
| Case Study 4: Hypothyroidism and Drug Metabolism                                         | 138 |
| Patient Story: Emma's Prolonged Sedation                                                 | 138 |
| Case Study 5: Inflammatory Bowel Disease and Drug Absorption                             | 138 |
| Patient Story: John's Inconsistent Response to Oral Medications                          | 138 |
| <b>ENZYME-BASED INCOMPLETE METABOLISM</b>                                                | 139 |
| Case Study 1: Cytochrome P450 2d6 Deficiency and Codeine Toxicity                        | 140 |
| Patient Story: Emily's Codeine Overdose                                                  | 140 |
| Case Study 2: Glucose-6-Phosphate Dehydrogenase Deficiency and Hemolytic Anemia          | 140 |
| Patient Story: Ahmed's Hemolytic Crisis                                                  | 140 |
| Case Study 3: Thiopurine S-Methyltransferase (TPMT) Deficiency and Azathioprine Toxicity | 141 |
| Patient Story: Rachel's Life-Threatening Myelosuppression                                | 141 |
| Case Study 4: Dihydropyrimidine Dehydrogenase (DPD) Deficiency And 5-FU Toxicity         | 141 |
| Patient Story: John's Severe 5-FU Toxicity                                               | 141 |
| Case Study 5: Aldehyde Dehydrogenase 2 (ALDH2) Deficiency and Alcohol Intolerance        | 142 |
| Patient Story: Mei's Social Struggles with Alcohol Intolerance                           | 142 |
| <b>CHEMICAL-INDUCED INCOMPLETE METABOLISM</b>                                            | 142 |
| Case Study 1: Grapefruit Juice and Statin Toxicity                                       | 143 |
| Patient Story: Mark's Rhabdomyolysis                                                     | 143 |
| Case Study 2: Alcohol And Acetaminophen-Induced Liver Toxicity                           | 143 |
| Patient Story: Sarah's Acute Liver Failure                                               | 143 |
| Case Study 3: Smoking and Theophylline Toxicity                                          | 143 |
| Patient Story: John's Theophylline Overdose                                              | 144 |
| Case Study 4: Herbal Supplements and Warfarin Interactions                               | 144 |
| Patient Story: Linda's Uncontrolled Bleeding                                             | 144 |
| Case Study 5: Pesticide Exposure and Reduced Drug Metabolism                             | 144 |
| Patient Story: Carlos's Unexplained Seizures                                             | 145 |
| <b>ENVIRONMENTAL IMPACT ON INCOMPLETE METABOLISM</b>                                     | 145 |
| Case Study 1: Air Pollution and Cytochrome P450 Enzyme Induction                         | 145 |
| Patient Story: Sarah's Struggle with Asthma Control                                      | 146 |
| Case Study 2: Pesticide Exposure and Inhibition Of Metabolic Enzymes                     | 147 |
| Patient Story: Carlos's Unexplained Seizures                                             | 147 |
| Case Study 3: Heavy Metal Exposure and Disruption of Nutrient Metabolism                 | 147 |



|                                                                                        |     |
|----------------------------------------------------------------------------------------|-----|
| Patient Story: Linda's Chronic Fatigue and Anemia .....                                | 148 |
| Case Study 4: Endocrine Disruptors and Thyroid Hormone Metabolism .....                | 148 |
| Patient Story: James's Weight Gain and Depression .....                                | 148 |
| Case Study 5: Environmental Toxins and Mitochondrial Dysfunction .....                 | 149 |
| Patient Story: Emily's Mitochondrial Myopathy .....                                    | 149 |
| <b>CONCLUSION</b> .....                                                                | 149 |
| <b>REFERENCES</b> .....                                                                | 150 |
| <b>CHAPTER 6 METABOLIC BIOMARKERS AS DIAGNOSTIC APPROACHES DURING METABOLISM</b> ..... | 158 |
| <i>Monika Rana, Prabhsharan Kaur and Varinder Singh</i> .....                          |     |
| <b>INTRODUCTION</b> .....                                                              | 158 |
| <b>HISTORY OF BIOMARKER</b> .....                                                      | 159 |
| Selection and Validation of Biomarkers .....                                           | 159 |
| Types of Biomarkers .....                                                              | 160 |
| What is an Ideal Biomarker? .....                                                      | 161 |
| Diagnostic Biomarkers .....                                                            | 161 |
| <b>ROLE IN DISEASE DIAGNOSIS</b> .....                                                 | 162 |
| <b>CASE STUDIES OF KEY DIAGNOSTIC BIOMARKERS</b> .....                                 | 162 |
| Imaging Biomarkers .....                                                               | 164 |
| PET Scan as Imaging Biomarker .....                                                    | 164 |
| CT Scan as Imaging Biomarker .....                                                     | 165 |
| Magnetic Resonance Imaging (MRI) as an Imaging Biomarker .....                         | 165 |
| <b>BIOCHEMICAL AND PHYSIOLOGICAL BIOMARKERS</b> .....                                  | 166 |
| Blood and Urine Biomarkers .....                                                       | 166 |
| Hormonal and Metabolic Biomarkers .....                                                | 167 |
| <b>VALIDATION AND STANDARDIZATION OF BIOMARKERS</b> .....                              | 167 |
| Proximity Extension Assay (PEA) .....                                                  | 168 |
| Multivariable Cox Regression and Machine Learning Techniques .....                     | 168 |
| Comparison with Gold Standard Immunoassays .....                                       | 168 |
| Multiplex Proteomic Analysis .....                                                     | 168 |
| Cell Type / Tissue Deconvolution .....                                                 | 169 |
| Differential Methylation Analysis .....                                                | 169 |
| DMR Annotation .....                                                                   | 169 |
| Linear Models of Methylation Levels on DMRs .....                                      | 169 |
| Machine Learning Models for Prediction of ACS Type .....                               | 169 |
| ACS Classification .....                                                               | 170 |
| ccfDNA Extraction .....                                                                | 170 |
| Whole-Genome Bisulfite Sequencing (WGBS) .....                                         | 170 |
| Targeted Methylation Sequencing .....                                                  | 171 |
| Cell Type / Tissue Deconvolution .....                                                 | 171 |
| Validation and Standardization of Biomarkers .....                                     | 171 |
| <i>Calmodulin</i> .....                                                                | 171 |
| <i>miRNAs, or Micro RNAs</i> .....                                                     | 172 |
| <i>Glial Fibrillary Acidic Protein (GFAP)</i> .....                                    | 172 |
| <i>Neurofilament Light Chain (NfL)</i> .....                                           | 172 |
| <i><math>\beta</math>-Synuclein and Total Prion Protein (t-PrP)</i> .....              | 172 |
| <i><math>\alpha</math>-Synuclein</i> .....                                             | 172 |
| <i>KL-40 (Chitinase-3-like protein 1)</i> .....                                        | 173 |
| <i>Heart-type Fatty Acid-Binding Protein (H-FABP)</i> .....                            | 173 |
| <i>Illness Biomarker Source</i> .....                                                  | 173 |

|                                                                                                             |     |
|-------------------------------------------------------------------------------------------------------------|-----|
| <i>Predictive and Diagnostic Value</i> .....                                                                | 173 |
| <b>TRACKING THE DEVELOPMENT OF NEURODEGENERATIVE DISEASES AND<br/>EVALUATING THERAPEUTIC RESPONSE</b> ..... | 173 |
| Chitinases .....                                                                                            | 174 |
| Phosphorylated Tau (p-tau) .....                                                                            | 174 |
| Neurofilament Light (NfL) .....                                                                             | 174 |
| Radiopharmaceutical Injection .....                                                                         | 174 |
| Getting Images .....                                                                                        | 175 |
| Image Interpretation .....                                                                                  | 175 |
| SPECT Applications .....                                                                                    | 175 |
| <b>ROLE AND MECHANISM OF MRI IN NEURODEGENERATIVE DISEASES</b> .....                                        | 176 |
| Diagnosis .....                                                                                             | 176 |
| Tracking the Progression of the Disease .....                                                               | 176 |
| Mechanism of MRI .....                                                                                      | 176 |
| <b>SPECIFIC APPLICATIONS IN NEURODEGENERATIVE DISEASES</b> .....                                            | 177 |
| <b>CONCLUSION</b> .....                                                                                     | 177 |
| <b>REFERENCES</b> .....                                                                                     | 177 |
| <b>CHAPTER 7 TREATMENT STRATEGIES AND THERAPEUTIC INNOVATIONS</b> .....                                     | 184 |
| <i>Saurav Kumar, Jyoti, Parijat Pandey and Dhirender Kaushik</i>                                            |     |
| <b>INTRODUCTION</b> .....                                                                                   | 184 |
| <b>IMPORTANCE OF ADDRESSING INCOMPLETE METABOLISM</b> .....                                                 | 185 |
| Prevention of Complications .....                                                                           | 185 |
| Improving Quality of Life .....                                                                             | 185 |
| Reducing Health Care Costs .....                                                                            | 186 |
| Development of Research and Therapeutics .....                                                              | 186 |
| Public Health Impact .....                                                                                  | 186 |
| <b>OVERVIEW OF TREATMENT STRATEGIES AND INNOVATIONS</b> .....                                               | 186 |
| <b>CURRENT TREATMENT STRATEGIES</b> .....                                                                   | 188 |
| Role of Diet in Managing Metabolic Disorders .....                                                          | 188 |
| Specific Dietary Strategies .....                                                                           | 188 |
| <i>Ketogenic Diets</i> .....                                                                                | 188 |
| <i>Low in Protein Diet</i> .....                                                                            | 192 |
| <i>Low Carbohydrate Diets</i> .....                                                                         | 192 |
| <i>Low-Fat Diets</i> .....                                                                                  | 194 |
| Pharmacological Treatments .....                                                                            | 194 |
| <i>Enzyme Cofactor</i> .....                                                                                | 194 |
| <i>Substrate Reduction Therapy (SRT)</i> .....                                                              | 195 |
| <i>Enzyme Inhibitors</i> .....                                                                              | 195 |
| <i>Ammonia Scavengers</i> .....                                                                             | 195 |
| <b>ENZYME REPLACEMENT THERAPY (ERT)</b> .....                                                               | 196 |
| Mechanism of Action .....                                                                                   | 196 |
| Clinical Applications .....                                                                                 | 196 |
| <i>Gaucher Disease</i> .....                                                                                | 197 |
| <i>Fabry Disease</i> .....                                                                                  | 197 |
| <i>Pompe Disease</i> .....                                                                                  | 197 |
| <i>Mucopolysaccharidosis (MPS) Disorders</i> .....                                                          | 197 |
| Benefits of Enzyme Replacement Therapy .....                                                                | 197 |
| <i>Symptom Management</i> .....                                                                             | 197 |
| <i>Disease Progression</i> .....                                                                            | 197 |
| <i>The Patient Outcomes</i> .....                                                                           | 198 |

|                                                                               |     |
|-------------------------------------------------------------------------------|-----|
| Limitations and Challenges .....                                              | 198 |
| Combination Therapies .....                                                   | 198 |
| <i>Synergistic Effects</i> .....                                              | 199 |
| <i>Reducing Drug Resistance</i> .....                                         | 199 |
| <i>Addressing Multiple Disease Mechanisms</i> .....                           | 199 |
| <i>Enhancing Patient Adherence</i> .....                                      | 199 |
| <b>INNOVATIVE THERAPEUTIC APPROACHES</b> .....                                | 199 |
| Gene Therapy .....                                                            | 199 |
| Methods of Gene Therapy for Incomplete Metabolism .....                       | 200 |
| <i>Viral Vector-Mediated Gene Therapy</i> .....                               | 200 |
| <i>AAV(Adeno Associated Virus)</i> .....                                      | 201 |
| <i>Lentiviral Vectors</i> .....                                               | 201 |
| <i>Adenovirus Vectors</i> .....                                               | 201 |
| Non-Viral Gene Delivery Methods .....                                         | 201 |
| <i>Plasmid DNA Delivery</i> .....                                             | 201 |
| Gene Editing With CRISPR-Cas9 .....                                           | 202 |
| RNA-Based Therapies (siRNA and mRNA) .....                                    | 202 |
| Approaches For Gene Therapy in Incomplete Metabolism .....                    | 202 |
| <i>Gene Augmentation Therapy</i> .....                                        | 203 |
| <i>Gene Editing</i> .....                                                     | 203 |
| Ex Vivo Gene Therapy .....                                                    | 205 |
| In vivo Gene Therapy .....                                                    | 205 |
| Clinical Applications and Success Stories .....                               | 206 |
| <i>Spinal Muscular Atrophy (SMA)</i> .....                                    | 206 |
| <i>Haemophilia</i> .....                                                      | 206 |
| <i>Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency</i> .....            | 206 |
| <i>Leber's Congenital Amaurosis (LCA)</i> .....                               | 206 |
| <i>Stem Cell Therapy</i> .....                                                | 206 |
| <b>CHALLENGES AND FUTURE PERSPECTIVES</b> .....                               | 208 |
| Pharmacological Chaperones .....                                              | 208 |
| Methods for Managing Incomplete Metabolism .....                              | 209 |
| Antioxidant Defence and Glutathione Regeneration .....                        | 209 |
| Carnitine-Mediated Acyl Group Buffering .....                                 | 209 |
| Mitochondrial Reductive Stress and its Management .....                       | 210 |
| Intermittent Fasting and Increasing Energy Demand .....                       | 210 |
| SGLT2 Inhibitors .....                                                        | 211 |
| <b>FUTURE DIRECTIONS IN RESEARCH AND INNOVATION</b> .....                     | 212 |
| <b>CONCLUSION</b> .....                                                       | 212 |
| <b>REFERENCES</b> .....                                                       | 213 |
| <b>CHAPTER 8 NUTRITIONAL AND LIFESTYLE INTERVENTIONS</b> .....                | 222 |
| <i>Arvinder Pal Singh, Ankush Goyal, Amit Aggarwal and Navjot Singh Sethi</i> |     |
| <b>INTRODUCTION</b> .....                                                     | 222 |
| <b>NUTRITIONAL INTERVENTIONS</b> .....                                        | 224 |
| Macronutrients .....                                                          | 225 |
| Role of Carbohydrates, Proteins, And Fats in Metabolism .....                 | 226 |
| Optimal Macronutrient Ratios for Supporting Complete Metabolism .....         | 227 |
| Micronutrients .....                                                          | 228 |
| <b>ESSENTIAL VITAMINS AND MINERALS INVOLVED IN METABOLIC PROCESSES</b> .....  | 228 |
| Deficiency and Supplementation Considerations .....                           | 229 |
| Dietary Patterns .....                                                        | 229 |

|                                                                                   |     |
|-----------------------------------------------------------------------------------|-----|
| Benefits of Balanced and Varied Diets .....                                       | 230 |
| Role of Fiber and Antioxidants .....                                              | 230 |
| Functional Foods and Supplements .....                                            | 230 |
| <b>PROBIOTICS AND PREBIOTICS</b> .....                                            | 231 |
| Omega-3 and Omega-6 Fatty Acids .....                                             | 231 |
| Herbal Supplements and Adaptogens .....                                           | 231 |
| <b>LIFESTYLE INTERVENTIONS</b> .....                                              | 232 |
| Physical Activity .....                                                           | 232 |
| Types of Exercises Beneficial for Metabolic Health .....                          | 233 |
| <i>Aerobic Exercise</i> .....                                                     | 233 |
| <i>Resistance Training</i> .....                                                  | 233 |
| <i>Flexibility and Balance Exercises</i> .....                                    | 233 |
| <i>Sleep and Circadian Rhythms</i> .....                                          | 234 |
| <b>IMPORTANCE OF SLEEP IN METABOLIC REGULATION</b> .....                          | 234 |
| Metabolic Processes During Sleep .....                                            | 234 |
| Sleep Deprivation and Metabolism .....                                            | 234 |
| Strategies for Improving Sleep Quality .....                                      | 235 |
| <b>STRESS MANAGEMENT</b> .....                                                    | 235 |
| Impact of Stress on Metabolism .....                                              | 236 |
| Techniques for Stress Reduction .....                                             | 236 |
| <b>HYDRATION</b> .....                                                            | 236 |
| Role of Water in Metabolic Processes .....                                        | 237 |
| Hydration Strategies and Guidelines .....                                         | 237 |
| <b>INTEGRATIVE AND HOLISTIC APPROACHES</b> .....                                  | 237 |
| Personalized Nutrition .....                                                      | 237 |
| Genetic and Epigenetic Considerations in Dietary Planning .....                   | 238 |
| Role of Personalized Nutrition in Optimizing Metabolic Health .....               | 238 |
| <b>INTEGRATIVE MEDICINES</b> .....                                                | 239 |
| Combining Conventional and Alternative Therapies .....                            | 239 |
| <b>CONCLUSION</b> .....                                                           | 239 |
| <b>REFERENCES</b> .....                                                           | 240 |
| <b>CHAPTER 9 FUTURE DIRECTIONS AND RESEARCH FRONTIERS</b> .....                   | 252 |
| <i>Sunil Dutt, Shiwank Rana, Satish Patnaik, Rajesh Kumar and Ravinesh Mishra</i> |     |
| <b>INTRODUCTION</b> .....                                                         | 253 |
| Pharmacogenomics and Personalized Medicine .....                                  | 253 |
| Diabetes Mellitus .....                                                           | 254 |
| Cancer .....                                                                      | 255 |
| Infectious Diseases .....                                                         | 256 |
| Cardiovascular Diseases .....                                                     | 257 |
| Inflammatory Diseases .....                                                       | 257 |
| Functions of Microbiome in Drug Metabolism .....                                  | 258 |
| Drug metabolism and its Metabolites .....                                         | 258 |
| Impact of Microbiome's Alteration .....                                           | 259 |
| Chronic Diseases and the Effect of Incomplete Metabolism .....                    | 259 |
| <i>Chronic Diseases</i> .....                                                     | 259 |
| <i>Effects of Incomplete Metabolism</i> .....                                     | 259 |
| Production and Development of Safer Drugs .....                                   | 260 |
| <i>New Drug Development</i> .....                                                 | 260 |
| <i>Drug Development and Production of Safer Drugs</i> .....                       | 260 |
| <i>Drug Metabolism and Safer Drugs</i> .....                                      | 261 |

|                                                                                                              |     |
|--------------------------------------------------------------------------------------------------------------|-----|
| <i>Cutting-Edge Biomarkers to Monitor Metabolism</i> .....                                                   | 261 |
| <i>Creatine and Glycogen</i> .....                                                                           | 261 |
| <i>Lactate and Pyruvate</i> .....                                                                            | 262 |
| <i>Leptin and Adiponectin</i> .....                                                                          | 262 |
| <i>Ghrelin</i> .....                                                                                         | 262 |
| <i>Uric acid</i> .....                                                                                       | 262 |
| Cytokines (IL-6, IL-10 and TNF- $\alpha$ ) .....                                                             | 262 |
| <i>Interleukin-6 (IL-6)</i> .....                                                                            | 262 |
| <i>Interleukin-10 (IL-10)</i> .....                                                                          | 263 |
| <i>Tumor Necrosis Factor-Alpha (TNF-<math>\alpha</math>)</i> .....                                           | 263 |
| <b>ASPECTS OF THE ENVIRONMENT AND LIFESTYLE</b> .....                                                        | 263 |
| Diet and Nutrition: Nutrient Deficiency .....                                                                | 263 |
| Overindulgence in Calories .....                                                                             | 264 |
| <b>PHYSICAL ACTIVITY</b> .....                                                                               | 264 |
| Sedentary Lifestyle .....                                                                                    | 264 |
| Excessive or Imbalanced Activity .....                                                                       | 265 |
| Toxin Exposure .....                                                                                         | 265 |
| Chronic Stress .....                                                                                         | 265 |
| Sleep Deprivation .....                                                                                      | 266 |
| <b>MICROBIOME HEALTH</b> .....                                                                               | 266 |
| Gut Dysbiosis .....                                                                                          | 266 |
| Exposure to Environmental Toxins .....                                                                       | 266 |
| Nutritional Exposure .....                                                                                   | 267 |
| High-calorie, Low-Nutrient Diets .....                                                                       | 267 |
| Socioeconomic Factors .....                                                                                  | 268 |
| Education and Awareness .....                                                                                | 268 |
| <b>GLOBALIZATION AND CULTURAL INFLUENCE</b> .....                                                            | 269 |
| Trends of Westernization of Diets .....                                                                      | 269 |
| Effects of Enzyme and Epigenetic Exposure .....                                                              | 269 |
| <b>ETHICS AND REGULATORY CONCERNS</b> .....                                                                  | 269 |
| Environmental Justice .....                                                                                  | 269 |
| Identifying Genetic Predispositions .....                                                                    | 270 |
| Personalized Medicine .....                                                                                  | 270 |
| Transcriptomics .....                                                                                        | 271 |
| Gene Expression Profiling .....                                                                              | 271 |
| Understanding Pathways .....                                                                                 | 272 |
| Systems Biology .....                                                                                        | 272 |
| Disease Research .....                                                                                       | 272 |
| Role of Transcriptomics and Pharmacogenomics in Personalized Medicine .....                                  | 273 |
| Proteomics .....                                                                                             | 273 |
| Metabolomics .....                                                                                           | 274 |
| Epigenomics .....                                                                                            | 274 |
| Applications in Metabolic Health .....                                                                       | 275 |
| <b>CONCLUSION</b> .....                                                                                      | 275 |
| <b>REFERENCES</b> .....                                                                                      | 276 |
| <b>CHAPTER 10 SUPPORTING CAREGIVERS AND PATIENTS IN MANAGING</b>                                             |     |
| <b>INCOMPLETE METABOLISM</b> .....                                                                           | 285 |
| <i>Ashima Thakur, Ashok Kumar, Rahul Sharma, Pooja Thakur, Pankaj Kalia, Rajesh Kumar and Shilpa Chandel</i> |     |
| <b>INTRODUCTION</b> .....                                                                                    | 286 |

|                                                                              |            |
|------------------------------------------------------------------------------|------------|
| <b>CONDEMNATION OF PATERNALISTIC CARE MODELS .....</b>                       | <b>287</b> |
| <b>ESSENTIAL FEATURES OF THE SYNERGETIC CARE MODEL .....</b>                 | <b>288</b> |
| Constructing a Support System .....                                          | 289        |
| Various Challenges Related to the Synergetic Care Model .....                | 289        |
| <b>VARIOUS TECHNIQUES TO IMPART HEALTH EDUCATION .....</b>                   | <b>290</b> |
| Encouragement of Patient Sovereignty and Collaborative Decision-Making ..... | 292        |
| <b>CASE STUDIES .....</b>                                                    | <b>293</b> |
| <b>CHALLENGES .....</b>                                                      | <b>295</b> |
| <b>CONCLUSION .....</b>                                                      | <b>295</b> |
| <b>REFERENCES .....</b>                                                      | <b>295</b> |
| <b>SUBJECT INDEX .....</b>                                                   | <b>304</b> |

## FOREWORD

In today's rapidly evolving world of medical science, the complex interplay between metabolism and health has gained increasing attention. This book titled "***Impact of Incomplete Metabolism on Health***" delves into a crucial yet often overlooked aspect of human physiology: the consequences of incomplete or impaired metabolic processes. Metabolism, the body's intricate system for converting food and other substances into energy, is essential for sustaining life. However, when these metabolic pathways are disrupted or incomplete, the effects can be far-reaching and profound, leading to a variety of health disorders.

This book offers a comprehensive exploration of how incomplete metabolism, whether due to genetic factors, environmental influences, or lifestyle choices, can adversely affect overall health. From rare metabolic disorders like phenylketonuria to more common conditions, such as diabetes, obesity, and cardiovascular disease, the book provides an in-depth analysis of how faulty metabolic processes contribute to disease development and progression. Readers will gain valuable insights into the underlying mechanisms of metabolism, the role of enzymes, and how nutrient deficiencies, toxins, and medications can exacerbate metabolic imbalances. Importantly, this book also highlights potential interventions, including dietary strategies and emerging therapies, to manage and mitigate the impact of incomplete metabolism.

Whether you are a healthcare professional, researcher, or someone seeking to understand the complexities of metabolism and its impact on health, this book will serve as an essential resource. It sheds light on the importance of early diagnosis, intervention, and personalized approaches to improve metabolic health and overall well-being.

**Brijesh Kumar**  
Department of Pharmacology  
Institute of Medical Sciences  
Banaras Hindu University  
Varanasi, Uttar Pradesh, India

## PREFACE

Incomplete metabolism refers to the body's inability to fully break down and process nutrients or compounds, leading to the accumulation of harmful byproducts. This can be caused by genetic factors, insufficient enzyme levels, or external influences, such as medications and certain foods. Incomplete metabolic pathways may result in the accumulation of intermediate chemicals inside tissues or the circulation, which may cause abnormal cellular activities and a range of health problems.

The metabolism of drugs is also impacted by incomplete metabolism. Some drugs can cause toxicity or adverse reactions if the liver is unable to adequately metabolize them. For instance, people with CYP2D6 deficiencies may not absorb medications like codeine or antidepressants well, which might result in either a harmful build-up or an inadequate therapeutic impact.

Chronic illnesses, including obesity, diabetes, and non-alcoholic fatty liver disease, can be brought on by environmental variables that affect metabolic pathways, in addition to hereditary problems. Examples of these factors include inadequate diet and exposure to chemicals. In general, the effects of inadequate metabolism can be extensive and severe; therefore, early detection and treatment are essential to the management of many disorders.

The book contains 10 chapters. Chapter 1 discusses the introduction to metabolism. In this chapter, the book begins with deep insights into the basics behind the metabolism and production of primary and secondary metabolites. Chapter 2 explains the understanding of incomplete metabolism. Chapter 3 tells about the metabolic pathways and intermediates produced during the various metabolic reactions. Chapters 4 and 5 explain the health implications of incomplete metabolism along with case studies of patients related to incomplete metabolism. Chapter 6 highlights the diagnostic approaches and biomarkers for the detection of metabolic disorders. Chapter 7 discusses the foundation for treatment strategies and therapeutic innovations. Both chapters 8 and 9 discuss the nutritional and lifestyle interventions along with future directions and research frontiers towards the impact of incomplete metabolism. Lastly, chapter 10 discusses the role of empowering patients and caregivers in controlling metabolic disorders.

**Rajesh Kumar**  
Maharaja Agrasen School of Pharmacy  
Maharaja Agrasen University  
Solan, Himachal Pradesh, India



## List of Contributors

|                           |                                                                                                                                                                                                        |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Ankit Awasthi</b>      | Chitkara University School of Pharmacy, Chitkara University, Rajpura, Punjab, India                                                                                                                    |
| <b>Ashutosh Kumar</b>     | Department of Ophthalmology, University of California Los Angeles, California, USA                                                                                                                     |
| <b>Anjna Sharma</b>       | Chitkara University School of Pharmacy, Chitkara University, Solan, Himachal Pradesh, India                                                                                                            |
| <b>Ashish Sharma</b>      | Washington University School of Medicine, Washington University in St. Louis, St. Louis, Missouri, United States                                                                                       |
| <b>Amit Aggarwal</b>      | Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India                                                                                                       |
| <b>Arvinder Pal Singh</b> | Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India                                                                                                       |
| <b>Ankush Goyal</b>       | Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India                                                                                                       |
| <b>Ashima Thakur</b>      | Faculty of Pharmaceutical Sciences, The ICFAI University, Baddi, Himachal Pradesh, India                                                                                                               |
| <b>Ashok Kumar</b>        | Faculty of Pharmaceutical Sciences, The ICFAI University, Baddi, Himachal Pradesh, India                                                                                                               |
| <b>Brijesh Kumar</b>      | Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India                                                                                    |
| <b>Devinder Kumar</b>     | Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar, Punjab, India<br>Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India |
| <b>Dhirender Kaushik</b>  | Department of Pharmaceutical Sciences, Gurugram University, Gurugram, Haryana, India                                                                                                                   |
| <b>Hitesh Chopra</b>      | Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India                                                            |
| <b>Jyoti</b>              | School of Pharmaceutical Sciences, MVN University, Palwal, Haryana, India                                                                                                                              |
| <b>Monika Rana</b>        | Department of Pharmacognosy, Laureate Institute of Pharmacy, Kangra, Himachal Pradesh, India                                                                                                           |
| <b>Navjot Singh Sethi</b> | IEC University, Solan, Himachal Pradesh, India                                                                                                                                                         |
| <b>Pankaj Kalia</b>       | Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India                                                                                                       |
| <b>Pratistha Singh</b>    | Department of Ophthalmology, University of California, Los Angeles, California, USA                                                                                                                    |
| <b>Prabhsharan Kaur</b>   | Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bhatinda, Punjab, India                                                                       |
| <b>Parijat Pandey</b>     | Department of Pharmaceutical Sciences, Gurugram University, Gurugram, Haryana, India                                                                                                                   |

|                        |                                                                                                                                         |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| <b>Pooja Thakur</b>    | Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India                                        |
| <b>Rajesh Kumar</b>    | Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India                                        |
| <b>Ravinesh Mishra</b> | School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences & Technology, Baddi, Solan, Himachal Pradesh, India     |
| <b>Rahul Sharma</b>    | Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Punjab, India                                             |
| <b>Sunil Dutt</b>      | Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India                                        |
| <b>Saurav Kumar</b>    | Department of Pharmaceutical Sciences, Gurugram University, Gurugram, Haryana, India                                                    |
| <b>Swati Pundir</b>    | School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, 173212, Himachal Pradesh, India |
| <b>Saurav Kumar</b>    | Department of Pharmaceutical Sciences, Gurugram University, Gurugram, Haryana, India                                                    |
| <b>Shiwank Rana</b>    | Dreamz College of Pharmacy, Sundernagar, Mandi, Himachal Pradesh, India                                                                 |
| <b>Satish Patnaik</b>  | Stein Eye Institute, Geffen School of Medicine, University of California, Los Angeles, California, USA                                  |
| <b>Shilpa Chandel</b>  | Banasthali Vidyapith, Department of Pharmacy, Banasthali, Rajasthan, Himachal Pradesh, India                                            |
| <b>Varinder Singh</b>  | Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bhatinda, Punjab, India        |
| <b>Yogendra Singh</b>  | School of Pharmaceutical Sciences, MVN University, Palwal, Haryana, India                                                               |

---

**CHAPTER 1**

---

**Insights into Metabolism****Sunil Dutt<sup>1</sup>, Ankit Awasthi<sup>2</sup>, Rajesh Kumar<sup>1,\*</sup> and Ashutosh Kumar<sup>3</sup>**<sup>1</sup> *Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India*<sup>2</sup> *Chitkara University School of Pharmacy, Chitkara University Rajpura Punjab, India*<sup>3</sup> *Department of Ophthalmology, University of California Los Angeles, California, USA*

**Abstract:** The present book chapter highlights the comprehensive epitome of metabolism, explaining the regulatory and intricate mechanisms involved. It commences with the introduction which encompasses drug metabolism pathways, enumerating linear, cyclic, and branched pathways then delves into the catabolic and anabolic pathways. The catabolic pathways explore glycolysis and the Krebs cycle, and anabolic pathways involve gluconeogenesis, protein synthesis, and lipogenesis. The further section overshadows discussion on energy in metabolism. This segment of the chapter discusses ATP as the energy currency, highlighting its structure, functions, and ATP hydrolysis. Further, it emphasizes energy transfer mechanisms that involve redox reactions. The other segments of the chapter cover the role of enzymes in metabolism, explaining catalytic functions and specificity. Afterward, enzyme regulation involves allosteric regulation and feedback inhibition. Finally, the book chapter delves the metabolism regulation, focusing on hormonal regulation, nutrient availability, and genetic-epigenetic regulation. Examining these various aspects, it is quite clear that the chapter provides a framework for understanding the complex nature of metabolism and its vital role in health and disease.

**Keywords:** Absorption, Acetylation, Active medications, Anabolic pathways, Catabolic pathways, Coupling reactions, Drug-metabolizing enzymes, Ecotoxicology, Elimination, Energy in metabolism, Enzymes in metabolism, Lipophilic molecules, Metabolism regulation, Metabolism, Pharmacodynamics, Pharmacokinetics, Phosphorylation, Prodrugs, Transformation, Xenobiotic.

**INTRODUCTION**

The study of drug metabolism, a branch of pharmacology and biochemistry, quickly advanced starting around 1950. It has significantly influenced pharmacokinetics, pharmacodynamics, ecotoxicology, and other biological fields.

---

\* **Corresponding author Rajesh Kumar:** Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India; E-mail: rajdhiman60@gmail.com

International rules increasingly require knowledge of the metabolism of medicines and other xenobiotics. The 19th century witnessed the most noteworthy achievements. The metabolism processes, such as acetylation, the synthesis of mercapturic acid, conjugation with glycine, sulfuric acid, and glucuronic acid, hydrolysis, reduction, and oxidation, were made clear [1]. The chemical sequence oxidation-conjugation created a number of pathways for different substrates and has become the cornerstone of modern xenobiochemistry [2].

Simply, medicines are small molecules that fall under the category of xenobiotics, or compounds that are not naturally occurring in the human body. Nonetheless, a variety of endogenous compounds, such as steroids and hormones, are occasionally referred to as drugs and are used to treat certain medical conditions. The term “metabolism” refers to the process by which an enzyme changes a chemical's moiety. The most well-known enzymes involved in drug metabolism are the reductases, hydrolases, and oxidases that make up the cytochrome P450s (CYP450s). The primary objective of metabolism is the elimination of endogenous and/or exogenous chemicals from the body [3].

In the metabolic process, there will be the conversion of lipophilic molecules into hydrophilic ones or will facilitate elimination. On the other hand, the drug-metabolizing enzymes transform compounds into their pharmacologically active form in many conditions. Prodrugs are pharmaceutically inactive drugs designed to treat absorption and bioavailability difficulties. They pass through a process of transformation in the body subsequent to absorption to become active medications. To get around ampicillin's low bioavailability, pivampicillin is produced as a prodrug that has the potential to hydrolyze into ampicillin after being absorbed into the bloodstream. A significant instance of a prodrug is the use of mycophenolate mofetil to improve the oral bioavailability of mycophenolic acid [4].

The byproducts of metabolism that are called metabolites can either be biologically active or inactive. The smooth endoplasmic reticulum (ER), mitochondria, and small intestinal epithelia of hepatocytes are the primary locations for five CYP450 enzymes that are crucial for drug removal. To a lesser extent, they are also present in the proximal tubules of the kidneys. The significance and essential functions of conjugating enzymes and drug transporters are becoming increasingly clear to humans. Modifications to these pathways may have an impact on a drug's pharmacokinetics and pharmacodynamics. Drugs interact with these pathways during their absorption, distribution, metabolism, and excretion [5].

## DRUG METABOLISM PATHWAYS

There are various and diverse ways that drug-food substances can be metabolized or biotransformed, including through the chemical processes of hydration, reduction, oxidation, hydrolysis, conjugation, and condensation. Studying these pathways is critical since a drug's metabolism might reveal whether or not it has pharmacological or toxicological effects. Phase I, also known as functionalization reactions, and Phase II, sometimes known as conjugative reactions, are the two stages that generally makeup drug metabolism (Table 1). The chemical processes are often connected to drug metabolism in phases I and II [6].

**Table 1. Phase I and Phase II reactions.**

| Phase I           | Phase II                      |
|-------------------|-------------------------------|
| Oxidation         | Glucuronidation/glucosidation |
| Reduction         | Sulfation                     |
| Hydrolysis        | Acetylation                   |
| Dethioacetylation | Methylation                   |
| Isomerisation     | Glutathione conjugation       |
| Hydration         | Amino acid conjugation        |

On the other hand, the drug and the food go through the drug metabolism process. It can undergo different types of pathways based on their structural flow and functionality. Here's an explanation of these pathways:

### Linear Pathway

In linear pathways, the drug undergoes a series of sequential biochemical transformations, with each step dependent on the previous one.

By converting acetaldehyde to acetate, mammals metabolize ethanol. By conversion to acetyl CoA, acetate is absorbed by the general metabolic pool. Although other organs subsequently metabolize the majority of the acetate, the liver is the primary organ that converts ethanol to acetate. Alcohol Dehydrogenase (ADH) is the enzyme that is principally responsible for converting ethanol to acetaldehyde by catalyzing the following reaction:  $\text{acetaldehyde} + \text{NADH} + \text{H}^+ \rightarrow \text{ethanol} + \text{NAD}^+$ .  $\text{NAD}^+$  is an essential coenzyme that accepts electrons during the oxidation of ethanol to acetaldehyde (Fig. 1).

It is reduced to NADH in the process. The availability of  $\text{NAD}^+$  is a limiting factor in ethanol metabolism. Since  $\text{NAD}^+$  is required for glycolysis, the citric acid cycle, and the electron transport chain, extensive ethanol metabolism can

---

**CHAPTER 2**

---

## Understanding Incomplete Metabolism

**Anjna Sharma<sup>1</sup>, Hitesh Chopra<sup>2,\*</sup>, Sunil Dutt<sup>3</sup> and Rajesh Kumar<sup>3</sup>**

<sup>1</sup> Chitkara University School of Pharmacy, Chitkara University, Solan, Himachal Pradesh, India

<sup>2</sup> Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India

<sup>3</sup> Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India

**Abstract:** An incomplete metabolism is a state in which the body is unable to completely break down certain chemicals, which results in the buildup of hazardous metabolites. In addition to enzyme deficits and hereditary problems, this condition may also be brought on by other causes that interfere with the normal metabolic processes. There are many different systems in the body that may be affected by incomplete metabolism. The symptoms that might occur from incomplete metabolism can vary greatly depending on the exact metabolic disease. Here, we will talk about the significance of early intervention in preventing or minimizing long-term problems, as well as the role that genetic testing plays in determining the precise metabolic abnormality. The chapter will also emphasize the difficulties associated with regulating incomplete metabolism as well as the necessity of conducting further research in order to produce medications that are more successful.

**Keywords:** Alcohol metabolism, Incomplete metabolism, Maple syrup urine disease, Phenylketonuria.

### INTRODUCTION

The body of an individual is subjected to a variety of external elements, including foodstuffs, poisons, dirt, airborne pollutants and sometimes some medicines [1]. All of these alien particles are referred to as xenobiotics. “Xeno” refers to something that is not native to our body and is therefore foreign [2]. The body has a system to expel these foreign particles once they enter it. This process is referred to as metabolism. Since medications are alien particles, they are also considered xenobiotics. Another name for the drug metabolism process is biotransformation [3]. Certain medications are metabolized to create hazardous byproducts which

---

\* **Corresponding author Hitesh Chopra:** Department of Biosciences, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu, India; E-mail: chopraontheride@gmail.com

can cause cancer or mutations. The body's primary location of metabolism is the liver. Some medications undergo first-pass metabolism before entering the bloodstream; this is known as the “first-pass effect.” The gastrointestinal tract, skin, kidneys, and other organs participate in drug metabolism. Drug metabolism occurs in two stages, known as phase I and phase II metabolic processes [4].

Hydroxylation, dealkylation, various oxidations, reduction, and hydrolysis are examples of phase-I processes. The main Phase-I enzymes are members of the cytochrome P450 family of enzymes (CYPs). The conjugation of several accessory groups, such as glutathione and glucuronic acid, to drug molecules occurs during Phase-II reactions. This process frequently results in improved water solubility, which aids in excretion [5].

### **COMPLETE VS. INCOMPLETE DRUG METABOLISM**

The term “complete metabolism” refers to the processes involving the complete conversion of a drug into its metabolites to facilitate the excretion of a drug from the body easily by utilizing Phase I and Phase II reactions [6]. This involves the breakdown of metabolite into a water-soluble compound to be excreted through urine and bile. Whereas in incomplete metabolism drug is not fully converted to its metabolite, leaving the parent drug or some partially formed metabolites within the body. This can be due to saturation of enzymes, drug interactions, genetic factors like polymorphisms in metabolic enzymes and some formulation factors [7].

A drug's duration of action, the possibility of the drug or its metabolites building up, and the danger of adverse effects or toxicity can all be brought on by incomplete metabolism (Fig. 1). To control these hazards, dose adjustments and monitoring could be required [8].

### **CHARACTERISTICS OF INCOMPLETE METABOLISM**

Incomplete metabolism can have several implications for the effectiveness of a drug, side effects or toxic effects of a drug, as well as the overall response of a patient to a drug [9]. The key characteristics include the elevation of the pharmacological effect of a drug like losartan, clopidogrel & tamoxifen, which needs to be metabolized to an active form or prodrug. The incomplete metabolism or activation may lead to reduced pharmacological effect and extended duration of action and accumulation.

Incomplete metabolism refers to an incomplete breakdown of food, which leads to the generation of intermediate compounds that are toxic to human health. Normally, inside the human body, there are majority of processes that take place

simultaneously to complete the process of metabolism [10]. These processes are often governed by bioenergetics and require proper oxygen supply, but no adequate oxygen to influence such processes may lead to incomplete metabolism. There are several factors that cause incomplete metabolism, including alcohol metabolism and Acetaldehyde accumulations, Phenylketonuria, maple syrup urine disease, and galactosemia [11, 12].




Fig. (1). Process of complete and incomplete metabolism.

### Alcohol Metabolism and Acetaldehyde Accumulation

The liver is the major site for Alcohol metabolism, which occurs through the involvement of liver enzyme known as alcohol dehydrogenase (ADH), which converts ethanol to acetaldehyde. Further, the metabolism of acetaldehyde involves enzymatic reduction with the help of Aldehyde dehydrogenase (ALDH), which changes the acetaldehyde to acetate [13]. Excessive alcohol intake or ALDH deficiency causes incomplete alcohol metabolism leading to acetaldehyde accumulation. Additionally, incomplete metabolism of alcohol is commonly seen in individuals with variation in ALDH2 genes, causing less enzymatic activation [14, 15]. This triggers the toxic effects responsible for the symptoms like nausea, flushing and liver damage and also causes cancer [16]. The chronic accumulation however, leads to the generation of raw oxygen stress, inflammation and severe health conditions like hepatitis and cirrhosis. The acetaldehyde has carcinogenic properties that cause serious health hazards. The accumulation of acetaldehyde



---

**CHAPTER 3**

---

**Metabolic Pathways and Intermediates****Jyoti<sup>1</sup>, Saurav Kumar<sup>2</sup>, Yogendra Singh<sup>1,\*</sup> and Sunil Dutt<sup>3</sup>**<sup>1</sup> School of Pharmaceutical Sciences, MVN University, Palwal, Haryana, India<sup>2</sup> Department of Pharmaceutical Sciences, Gurugram University, Gurugram, Haryana, India<sup>3</sup> Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India

**Abstract:** Metabolism is the chemical process that keeps living organisms alive by providing cells with energy to maintain normal cell functions and metabolic building blocks to produce new cellular components. Metabolism is, therefore, central to all life and comprises myriad biochemical pathways organised by myriad intermediates to form networks that convert nutrient substrates to metabolic products. This chapter describes the metabolic pathways and metabolic intermediates present in all cells, the enzymes that catalyse these reactions, the mechanistic details behind the biochemistry, and the roles that they play in obtaining energy, biosynthesis and cell regulation. It explores systems-level control of metabolic flux to adapt cell functions to environmental changes and discusses the serious consequences that result when control breaks down and so-called metabolic ‘disinsiders’ take over – as in metabolic disorders such as diabetes and obesity. It also discusses novel technologies and research paradigms driving progress in the world of metabolism, including new approaches to data analysis and drug discovery, and will define the future of this field in the coming decades. In this chapter, we describe the process of primary metabolism: how cells obtain energy and build new biological molecules such as proteins, lipids and nucleic acids.

**Keywords:** Biochemistry, Cell function, Metabolic pathways, Metabolism.


**INTRODUCTION**

The word “metabolism,” derived from the Greek word meaning “change,” refers to the sum of all chemical processes that are targeted toward enabling life to take place in the cells of living organisms. A combination word originates from the Greek roots “meta,” meaning “over,” and “ballein,” meaning “to throw. The totality of the essential chemical processes occurring inside a cell is referred to as metabolism. The last three decades of the sixteenth century represented the start

---

\* **Corresponding author Yogendra Singh:** School of Pharmaceutical Sciences, MVN University, Palwal, Haryana, India; E-mail: yogesigh1978@gmail.com

of the first recorded and more detailed studies on metabolism. This age represented the time when instrumentation started to be coupled with direct observation so that quantification, and therefore validation, was introduced to the sciences, in this instance, within biological systems [1]. Metabolic balance can no longer be achieved under extreme external parameters or when internal control is contaminated by genetic or epigenetic alterations. This leads, in response to aging, to the evolution of disorders such as metabolic syndrome or cancer and, ultimately, death [2]. The chemical apparatus that allows cells to convert some chemical feedstocks into chemical energy (ATP, NADPH) and into building blocks (small organic molecules, activated coenzymes) used to synthesize biomass is generally referred to as metabolism. In practice, all the metabolic reactions are steady-state processes (almost) catalysed by enzymes. Non-enzymatic cellular responses are rare, as shown in Fig. (1).



**Fig. (1).** Metabolic reactions.

Proteins catalyze metabolic processes, and biochemists have spent decades studying the *in vitro* kinetic characteristics of these enzymes. Through these initiatives, it became clear that acute modulation of enzyme activity is possible and essential to maintaining metabolic homeostasis. Allosteric interactions with the metabolites themselves or post-translational changes brought on by intracellular signal transduction pathways are two possible mechanisms by which regulation is mediated.

More recently, cell biologists have become interested in the regulation of enzymes after noticing that variations in growth circumstances frequently cause diffusely dispersed enzymes to condense into one or more distinct foci that are readily

observed by light microscopy. The most appropriate way to characterize this transition from a soluble to a condensed state is as a phase separation.

Anabolism uses energy to produce biomolecular polymers and macromolecules. When they are reduced to smaller molecules during metabolism, energy is released. Living things always need energy to maintain cellular and whole-body functions. Mechanical work (contraction and movement of cells), active transfer of ions and substrates ( $K^+$ ,  $Mg^{2+}$ , and  $Ca^{2+}$ , for example, in heart contraction), and the manufacture of complex macromolecules (like glycogen) all require energy [3, 4].

## METABOLIC PATHWAY

Chemical products go through a succession of metabolic intermediates to become the substrate molecule or molecules in metabolic pathways and cycles, which ultimately result in a final product or products. Large molecules, for instance, are broken down into glucose by one metabolic pathway for carbohydrates. Chemical transformation occurs in all substrates in reactions that are part of metabolic cycles (if the reaction moieties are conserved) or pathways (if the reactions are arranged linearly). Substance deterioration that ultimately results in the creation of  $CO_2$  is referred to as substrate oxidation. However, there are a number of reasons why an oxidative pathway like this could be disrupted. For example, during the oxidation of glucose, low oxygen levels cause lactate to be produced instead of  $CO_2$  and water. Certain substrates, but not all of them, can also be transformed into the fundamental components of biosynthetic reactions [5, 6].

A metabolic pathway refers to a series of interconnected processes in which chemical events occur within a cell. The products, reactants, or intermediates of an enzymatic process whose modification entails a sequence of chemical reactions mediated by enzymes are referred to as metabolites [7]. The product of one enzyme usually becomes the substrate for the next enzyme in most metabolic pathways. The by-products are expelled out of the cell as they are considered waste. Depending on their location in eukaryotic cells and the significance they may have towards that compartment of a cell, the various metabolic pathways perform different functions. The electron transport chain and oxidative phosphorylation, for example, occur in the mitochondrial membrane, whereas fatty acid synthesis, glycolysis, and the pentose phosphate pathway are all located in the cytoplasm of a cell [8].

The pathways are needed by the organism for homeostasis, the flow of metabolites through a pathway is decided by the cellular requirement and substrate availability. The end product of a particular metabolic pathway may be stored for future use, utilised immediately, or may serve as the starting material in

## Health Implications of Incomplete Metabolism

Pankaj Kalia<sup>1</sup>, Swati Pundir<sup>2</sup>, Ashish Sharma<sup>3</sup>, Rajesh Kumar<sup>1</sup> and Amit Aggarwal<sup>1,\*</sup>

<sup>1</sup> Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India

<sup>2</sup> School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan – 173212, Himachal Pradesh, India

<sup>3</sup> Washington University School of Medicine, Washington University in St. Louis, St. Louis, Missouri, United States

**Abstract:** The important effects of incomplete metabolism on human health are examined in this work, with particular attention to how it may play a role in the etiology of long-term conditions like diabetes, obesity, and mitochondrial diseases. Nutritional deficits, the buildup of hazardous metabolites, and a disturbance of biochemical equilibrium are all consequences of metabolic pathway disruption. The classic cases of phenylketonuria (PKU) and maple syrup urine disease (MSUD) are the grave neurological and developmental effects of metabolic pathway disruption. G6PD insufficiency is an example of how incomplete drug metabolism, which can be caused by genetic polymorphisms, enzyme deficiencies, or hepatic/renal impairments, can lead to metabolic toxicity and drug buildup. Deficiencies in vital vitamins (B<sub>12</sub>, D, A, K) and minerals (calcium, iron) result in metabolic inefficiencies and clinical aftereffects, such as anemia and neurotoxicity. Nutrient metabolism is also compromised. Lipid intermediate buildup, oxidative stress, and systemic inflammation are all influenced by lipid metabolic abnormalities, which are especially prevalent in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). By affecting ATP synthesis and redox equilibrium, mitochondrial dysfunction aggravates metabolic diseases further. Oxidative stress aggravates illnesses, such as myopathies and lactic acidosis. Novel therapeutic approaches, such as enzyme replacement therapy (ERT), CRISPR-Cas9 gene therapy, and nanotechnology-based methods, present intriguing paths toward pharmacogenomics-driven enzyme regulation and metabolic function restoration, as well as toward precision medicine.

**Keywords:** CRISPR-Cas9 gene editing therapy, Hepatic lipid peroxidation, Inborn errors of metabolism, Metabolic dysregulation, Micronutrient malabsorption, Mitochondrial bio-energetic failure, Phenylalanine hydroxylase deficiency, Toxic metabolite accumulation, Xenobiotic metabolism impairment.

\* Corresponding author Amit Aggarwal: Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India; E-mail: amitaggarwal78@yahoo.co.in

## INTRODUCTION

This chapter titled “Health Implications of Incomplete Metabolism” explores the adverse effects that arise when the body cannot efficiently convert nutrients into energy and essential biochemical substances. Metabolism includes all the chemical processes necessary for sustaining life, encompassing both catabolic reactions that break down molecules for energy and anabolic reactions that use this energy to build cellular components like proteins and nucleic acids [1]. When metabolism is incomplete or disrupted, it can lead to substantial health problems like accumulation of metabolic byproducts, energy and nutrient deficiency, obesity, and metabolic syndromes, along with a few chronic and developmental disorders. The incomplete metabolism of certain substances can cause harmful byproducts to accumulate in the body, leading to various health complications. Phenylketonuria (PKU) is a notable example, where the body fails to process the amino acid phenylalanine, leading to its toxic buildup. This accumulation can cause intellectual disability and other neurological issues if not controlled through dietary management. Inefficient metabolism can lead to insufficient energy production, which is commonly seen in mitochondrial diseases. These conditions, where the mitochondria do not produce enough energy, typically present with symptoms like muscle weakness, fatigue, and various systemic problems [2]. These issues often stem from improper regulation of hormones involved in metabolism, like insulin and leptin, emphasizing the importance of maintaining metabolic health to prevent chronic diseases. Incomplete metabolism can cause nutrient deficiencies even with sufficient dietary intake. Conditions like malabsorption syndromes, including celiac disease, impede the body's ability to digest and absorb nutrients properly, leading to deficiencies in essential vitamins and minerals. These deficiencies can significantly impact overall health and well-being [3]. Prolonged metabolic inefficiencies can also lead to chronic diseases. For example, diabetes mellitus is marked by improper glucose metabolism, resulting in consistently high blood sugar levels and related complications like neuropathy, nephropathy, and cardiovascular diseases. Focusing on metabolic health is essential for preventing and managing these chronic conditions [4, 5]. Incomplete metabolism can impact growth and development, especially in children. Disorders like maple syrup urine disease (MSUD) hinder the breakdown of certain amino acids, causing severe neurological damage and developmental delays if not properly managed. Initial diagnosis and interposition are crucial in reducing the impact of these disorders on development [6]. Recognizing the health implications of incomplete metabolism is vital for the early diagnosis, management, and treatment of metabolic disorders. Ongoing research and medical advancements continue to enhance our ability to identify and address these metabolic issues, improving the quality of life for those affected. Sustained efforts

in this field are essential for developing effective strategies to mitigate the health impacts of incomplete metabolism [6, 8, 9, 11].

### **Metabolic Pathways and Disorders**

Metabolic pathways consist of a series of chemical reactions occurring within cells, which are essential for maintaining cellular function and overall health. Disruptions in these pathways can result in metabolic disorders with significant health impacts [7].

For instance, the urea cycle is a pathway that converts ammonia to urea for excretion. Any enzyme defect in the urea cycle can cause an increase in ammonia, characterized by high levels of ammonia in the body, which can lead to severe neurological indications and be fatal if untreated [8, 9].

Phenylketonuria (PKU) is a genetic metabolic syndrome resulting from an insufficiency in the enzyme phenylalanine hydroxylase, which converts phenylalanine into tyrosine. Lacking this enzyme, phenylalanine builds up in the body, potentially causing severe intellectual disability, seizures, and other serious health problems if not managed with a strict low-phenylalanine diet [10].

MSUD is a genetic condition impacting the body's capability to metabolize specific amino acids. The disorder is termed for the sweet-smelling urine of diagnosed persons, similar to maple syrup. Without appropriate treatment, MSUD can result in severe neurological damage, developmental delays, and even death. Treatment generally involves a specialized diet low in these amino acids and close medical monitoring [6].

Mitochondrial disorders comprise a group of metabolic conditions resulting from dysfunctions in the mitochondria, often causing muscle weakness, neurological issues, and various other symptoms. Since mitochondria produce most of the body's energy, defects in these organelles can lead to widespread and debilitating effects [11, 12].

Managing and treating metabolic disorders typically involves dietary changes, medications, and other interventions to address the underlying metabolic imbalance. For instance, people with PKU need a low-phenylalanine diet to prevent its buildup in the body. Those with MSUD require a diet low in the specific amino acids they cannot metabolize. In some cases, enzyme replacement therapy or other medical treatments may be needed to manage symptoms and prevent complications [6].

---

**CHAPTER 5**

---

**Case Studies and Patient Stories****Devinder Kumar<sup>1,2</sup>, Brijesh Kumar<sup>4</sup>, Rajesh Kumar<sup>2,\*</sup> and Pratistha Singh<sup>3</sup>**<sup>1</sup> *Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela, Ropar, Punjab, India*<sup>2</sup> *Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India*<sup>3</sup> *Department of Ophthalmology, University of California, Los Angeles, California, USA*<sup>4</sup> *Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India*

**Abstract:** Pharmacological metabolism issues put patient safety at risk by raising the possibility of side effects and inadequate treatment results. This summary attempts to explain the challenges associated with drug metabolism, particularly long-term polypharmacy with metabolites - when an unintended change has direct and clinically meaningful effects. This is done through a series of cases and patient stories. Metabolism typically consists of a series of enzymatic reactions that occur primarily in the liver and result in drugs being converted into water-soluble forms for excretion. Nevertheless, it is a factor that can be disrupted by genetic polymorphisms, liver diseases affecting its expression or function, drug interactions, and age-related changes in physiological mechanisms. Metabolites can lead to bioaccumulation of a drug, poor therapeutic effects, or adverse events if metabolism is incomplete. A patient with a CYP2D6 enzyme deficiency may convert codeine to morphine more slowly, resulting in inadequate pain relief. Another example is a distant psychiatric patient with underlying liver disease who experiences significant inadequacy of benzodiazepine metabolism, leading to prolonged sedation and respiratory depression. There is also an example of polypharmacy, in which a patient taking multiple medications, including a strong CYP3A4 inhibitor, receives a toxic amount of a normally safe dose because the metabolic clearance rate is reduced. They are important examples of incomplete drug metabolism and underscore the imperative incorporation of precise, personalized medicine techniques, including genetic testing, close monitoring of liver function tests (which would account for gender differences in response), and thorough consideration of possible interactions between pharmaceutical agents that contribute to individual variability. This, in turn, allows healthcare professionals to provide more personalized treatment, minimize the risk of side effects, and improve patient outcomes.

---

\* **Corresponding author Rajesh Kumar:** Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India; E-mail: rajdhiman60@gmail.com

**Rajesh Kumar (Ed.)**

**All rights reserved-© 2025 Bentham Science Publishers**

**Keywords:** Disease, Drug interactions, Drug metabolism, Personalized medicine techniques, Pharmacogenomics.

## INTRODUCTION

Metabolism, the process by which our bodies convert food into energy, involves a complex series of chemical reactions occurring in every cell. While it's essential for sustaining life, this process can sometimes encounter disruptions, leading to various metabolic issues [1]. Unfortunately, some other factors can lead to (partially) inefficient nutrient metabolism, such as genetic diseases, changes in the environment, and food-drug interactions. Investigating these interactions is essential to making meaningful progress in the prevention and treatment of metabolic disorders [2]. Impairment of the body or organ's metabolic process through drug interactions leads to undesirable and serious health consequences, including the accumulation of toxic substances and even therapeutic failure [3]. These may be due to genetic factors, comorbidities, high glucose food intake, and increased consumption of multiple medications. The case studies highlight the need for individualized care and judicious use of medications in patients at risk of side effects [4].

This disruption can result in the incomplete metabolism of drugs, as well as endogenous or xenobiotic substances, which in turn alters their pharmacokinetics and/or pharmacodynamics. Such issues become especially concerning when diseases impair key metabolic organs like the liver and kidneys. The case studies in this article highlight the challenges of disease-related incomplete metabolism and demonstrate how these complications can significantly affect patient care [5]. Enzyme deficiencies or variations are also of great relevance as they can influence drug therapy, nutrition, and health in general. Enzymes are important for the metabolism of substances *in vivo*, and their abnormality can potentially trigger drug accumulation, acute toxicity, or treatment failure [6]. Here, we present case studies that illustrate the difficulties of incomplete metabolism in relation to enzyme systems. CIIM is a phenomenon in which exogenous chemicals (*e.g.*, environmental toxins, drugs, or dietary components) disrupt the normal metabolic process and instead produce different results. This disorder can lead to the accumulation of unmetabolized elements, leading to toxicity or treatment failure. These case studies demonstrate the importance of understanding and controlling these interactions in clinical practice [7]. In addition, environmental factors greatly influence metabolism by preventing the complete breakdown of nutrients, drugs, or toxins, thus leading to the accumulation of toxic substances in harmful concentrations. This also results in ineffective drug action and disruption of various biochemical pathways. Environmental factors play an important role



in metabolic impairment by highlighting case studies that help drive greater environmental awareness and targeted treatment (Fig. 1).

Moreover, environmental factors significantly affect metabolism by hindering the full breakdown of nutrients, drugs, or toxins, resulting in the buildup of toxic substances at harmful levels. This can lead to ineffective drug action and the disruption of critical biochemical pathways. Case studies emphasizing the role of environmental factors in metabolic impairment help raise awareness of these issues and promote the development of more targeted treatments and strategies for mitigating environmental impacts on health [8, 9].




Fig. (1). Incomplete metabolism.

### ROLE OF FOOD INTERACTION IN INCOMPLETE METABOLISM

Food-drug interactions are critical to drug metabolism and can result in incomplete or altered drug processing. Components of the diet, including macronutrients, vitamins, phytochemicals, and alcohol, can alter the activity of metabolic enzymes, thereby affecting the bioavailability, effectiveness, and safety

## Metabolic Biomarkers as Diagnostic Approaches During Metabolism

Monika Rana<sup>1</sup>, Prabhsharan Kaur<sup>2,\*</sup> and Varinder Singh<sup>2,\*</sup>

<sup>1</sup> Department of Pharmacognosy, Laureate Institute of Pharmacy,, Kangra, Himachal Pradesh, India

<sup>2</sup> Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bhatinda, Punjab, India

**Abstract:** Over the past ten years, there has been a noticeable growth in the use of biomarkers as early warning systems in the assessment of disease risk. Indicators of normal biological processes, pathological processes, or pharmacological responses to treatment are known as biomarkers. Biochemical indicators are important tools for guiding illness care since they provide important information about a patient's overall functional status and inflammatory state. The last few decades have seen the development and establishment of nanotechnology, which has led to the rise of new methods for the extraction of nanoscale biomarkers. This overview highlights the definitions, background, features, classifications, and the identification, verification, and standardization of biomarkers. Also discussed are the numerous new technologies in discovery and the possible use of biomarkers in the previous 10 years for the diagnosis, prognosis, and therapy of different diseases. The primary objective of this review is to encourage readers to investigate novel directions in biomarker development and research.

**Keywords:** Biomarkers, Diagnostic biomarkers, Imaging biomarkers, Technology, Validation.

### INTRODUCTION

A biological molecule that denotes a healthy or unhealthy process is called a biomarker. It exists in blood, lymph, and other body fluids (such as urine, tears, saliva, sweat, *etc.*) or tissues. It changes into a form that is molecular, cellular, or biochemical, making a measurement predictable and accurate. It is useful for monitoring and diagnosing physiological, pathological, and responses to drug treatment processes [1]. It is also referred to as a signature molecule and

---

\* **Corresponding authors Prabhsharan Kaur and Varinder Singh:** Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bhatinda, Punjab, India; E-mails: prabhsharanhayer@gmail.com; varinderjassal17@gmail.com

molecular marker. Biomarkers are quantifiable and do not reflect an individual's feelings or functions. Physiological parameters (*e.g.*, blood pressure, heart rate), biochemical markers (*e.g.*, alanine transferase, alkaline phosphatase, and bilirubin), x-ray results, angiography and magnetic resonance imaging, and intricate histologic and genetic testing of blood, genes, DNA, RNA, platelets, enzymes, hormones, and biomolecules, such as carbohydrates, proteins, lipids, and other tissues, are a few examples of biomarkers [2]. Biomarkers usually provide information about the progression of a disease, an early warning of the condition before symptoms appear, and/or treatment recommendations [3].

The failure rate is one of the main issues facing drug development today. During that phase, nine out of ten might not succeed. A new generation of biomarkers is required to increase the success rate and efficiency of drug development. These biomarkers should be more informative and able to alert developers early on to potential toxicity or lack of efficacy in their drug, giving them an early indication of what is likely to work and fail. Thus, those that are still in the development stage are considered biomarkers. In the past few years, biomarkers have gained importance in drug discovery as they can help determine the mechanism of action of a treatment, look into efficacy and toxicity signals early in the development process, and identify patients who are likely to respond to therapy [4].

## **HISTORY OF BIOMARKER**


It's possible to argue that the earliest biomarker was discovered by Hindu scholars in 1500 B.C. in India, when they observed that the high sugar content of diabetes patients' urine attracted ants. However, with the development of modern medicine much later, in the 20th century, came the term “biomarker”. The term “biochemical markers” and related terms originated in scientific journals in the 1940s and 1950s [5]. The first papers identifying biomarkers with a clinical application—cancer—were published in the 1970s. The term “biomarker” refers to a biological marker, as defined by the National Institutes of Health Biomarkers Definitions Working Group in 2000. As the internationally recognized definition of a biomarker in clinical pharmacology, this one has gained widespread acceptance. The development of modern medicine in the 20th century, however, introduced with it the term “biomarker” and numerous synonyms [6]. Some highlights are included in Fig. (1).

## **Selection and Validation of Biomarkers**

The selection and validation of a biomarker involve several criteria that need to be taken into account. It takes multiple stages to choose the best biomarker:

- The selection and identification of the interest's endpoint.

- The identification of the biomarker(s) unique to the outcome of interest, taking into account the biomarker's sensitivity, specificity, and significance with respect to health outcome or pathological change over time.
- The setup of a database to record the connection between the endpoint, potential biomarkers, and chemical exposure.
- A preference for non-invasive methods and consideration of specimens that might be available for analysis, with a focus on maintaining the specimen's integrity between collection and analysis.
- Assessment or forecast of the risk to the health of people, either for the broader public or a specific subgroup [6, 7].



**Fig. (1).** Historical turning points in the discovery of biomarkers in contemporary biomedicine.

## Types of Biomarkers

Biomarkers can be classified based on different parameters: their features, clinical uses, and techniques from the fields of genetics and molecular biology (Fig. 2).

As per the genetic and molecular biology approach, there are three different kinds of biomarkers: Type 0, Type 1, and Type 2. Natural history biomarkers may be referred to as Type 0 biomarkers, drug activity biomarkers, or Type 1 biomarkers; they show the result of medication intervention, and Type 2 biomarkers are

## CHAPTER 7

## Treatment Strategies and Therapeutic Innovations

Saurav Kumar<sup>1</sup>, Jyoti<sup>2</sup>, Parijat Pandey<sup>1</sup> and Dhirender Kaushik<sup>1,\*</sup>

<sup>1</sup> Department of Pharmaceutical Sciences, Gurugram University, Gurugram, Haryana, India

<sup>2</sup> School of Pharmaceutical Sciences, MVN University, Palwal, Haryana, India

**Abstract:** Incomplete metabolism, a condition characterized by the inability of cells to metabolize nutrients fully, has been linked to various health issues. This chapter provides an overview of the current treatment strategies and therapeutic innovations aimed at addressing the health impacts of incomplete metabolism. We discuss the traditional medical diet and cofactor treatments for inborn errors of metabolism, as well as enzyme replacement therapy and small molecule therapies as alternative approaches. Additionally, we explore the role of antioxidant defense, glutathione regeneration, and carnitine-mediated acyl group buffering in mitigating mitochondrial reductive stress and the potential benefits of intermittent fasting, increasing energy demand through strategies such as cold exposure and hypobaric hypoxia, and the use of SGLT2 inhibitors in promoting beiging of adipocytes. Finally, we highlight the future directions in gene therapy and cell reprogramming for inborn errors of metabolism, as well as the potential for repurposing existing drugs and the development of novel treatments through high-content screenings. This comprehensive review aims to provide a detailed understanding of the current treatment landscape and therapeutic innovations for incomplete metabolism, with the goal of improving patient outcomes and enhancing our understanding of this complex condition.

**Keywords:** Incomplete metabolism, Metabolism, Therapeutic innovations, Treatments.

### INTRODUCTION

Incomplete metabolism refers to a situation where the body's metabolic processes are impaired, leading to an inability to fully break down, convert, or utilize nutrients and other biochemical substances. These include all the chemical reactions that comprise the living condition of cells and organisms, and thus the pathways involved in it are those such as glycolysis, citric acid cycle, and oxidative phosphorylation. These metabolic pathways are responsible for

\* Corresponding author Dhirender Kaushik: Department of Pharmaceutical Sciences, Gurugram University, Gurugram, Haryana, India; E-mail: dkaushik.apti@gmail.com

converting food into energy, making up the building blocks that include proteins, lipids, and nucleic acids and ridding the body of waste products [1].

In normal metabolic conditions, the substrates are driven by the enzymes through these pathways to provide for the controlled processing of the metabolic by-products and their excretion. However, in conditions of incomplete metabolism, one or more steps of these pathways could get disrupted due to enzyme insufficiency or genetic disruption, among other factors that do not allow the complete processing of metabolic intermediates [2]. Consequently, few toxic substances may accumulate due to this process, or essential products may not get synthesized, thus leading to various metabolic disorders. Examples of incomplete metabolism include:

**Phenylketonuria (PKU):** The failure of the body to change phenylalanine into tyrosine due to the absence of an enzyme called phenylalanine hydroxylase; toxic accumulation of phenylalanine causes damage to the brain [3].

**Maple Syrup Urine Disease (MSUD):** This is a defect in the branched-chain alpha-keto acid dehydrogenase complex. It results in the accumulation of the branched-chain amino acids and their toxic by-products [4].

**Lysosomal Storage Disorders:** These include disorders like Gaucher's disease, where there is a deficiency of the enzyme glucocerebrosidase, which in turn causes intracellular accumulation of glucocerebroside [5].

## IMPORTANCE OF ADDRESSING INCOMPLETE METABOLISM

### Prevention of Complications

If incomplete metabolism is left untreated, it can become the only cause of serious complications like developmental delay, neurological damage, organ damage, and even death. For example, PKU, if allowed to remain untreated, could result in serious intellectual disability [6].

### Improving Quality of Life

Management of metabolic disorders effectively can improve the quality of life among patients. For instance, dietary management in PKU allows patients to lead normal lives by preventing toxic effects caused by the buildup of phenylalanine [7].

### **Reducing Health Care Costs**

Early diagnosis and early intervention reduce the management costs of the long-term complications associated with metabolic disorders. For example, newborn screening for metabolic disorders prevents hospitalization and other costly treatments resulting from the advanced stages of the disease [6].

### **Development of Research and Therapeutics**

Knowledge of mechanisms underlying incomplete metabolism may provide the impetus needed in the development of new therapies. Gene therapies, emerging enzyme replacement therapies, and other novel approaches give promise for the cure or effective management of diseases caused by these disorders [8].

### **Public Health Impact**

Metabolic disorders, although individually rare, collectively contribute significantly to public health burdens. Addressing these conditions through effective treatment strategies can reduce the overall burden on healthcare systems.

## **OVERVIEW OF TREATMENT STRATEGIES AND INNOVATIONS**

The treatment strategies for incomplete metabolism are diverse and have evolved tremendously over the years, right from simple dietary intervention to sophisticated gene and stem cell therapies. A few of them are as follows:

**Dietary Interventions:** Dietary control is the fundamental approach for treating numerous metabolic illnesses, and it is strongly recommended in this case as well. The following are measures that follow the principle of restricting the intake of substances that an enzyme deficiency is unable to metabolize properly. For example:

***Low-Phenylalanine Diet:*** In PKU, this diet is employed to prevent an accumulation of phenylalanine.

***Low-Protein Diets:*** In urea cycle disorders, low-protein diets help promote the limitation of ammonia production.

***Pharmacological Treatments:*** A prime significance is attached to drugs for symptom-free and disease-preventing strategies. These include:

**Substrate Reduction Therapy:** Drugs that decrease the formation of toxic substrates.

---

**CHAPTER 8**

---

**Nutritional and Lifestyle Interventions**

**Arvinder Pal Singh<sup>1</sup>, Ankush Goyal<sup>1,\*</sup>, Amit Aggarwal<sup>1,\*</sup> and Navjot Singh Sethi<sup>2</sup>**

<sup>1</sup> *Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India*

<sup>2</sup> *IEC University, Solan, Himachal Pradesh, India*

**Abstract:** Nutritional and lifestyle interventions are crucial in shaping humans mental and physical health and well-being over time. Based on the most recent research and evidence-based practices, the diet and lifestyle choices we make have an impact on health outcomes. It delves into the mechanisms through which specific interventions can improve health and lower the risk of chronic diseases. The effect of dietary patterns on health is a key focus. Numerous studies demonstrate the significant influence that dietary decisions have on the development and course of chronic illnesses, such as obesity, diabetes, and cardiovascular disease. A diet rich in fruits, vegetables, whole grains, and lean proteins and low in processed foods, sugar, and saturated fats can lower the risk of developing disease and raise the probability of staying healthy. The general state of health and metabolic processes are also significantly impacted by micronutrients. Several health problems, including a weakened immune system, cognitive decline, and weakened bone health, are linked to deficiencies in micronutrients. When needed, adequate intake of vitamins, minerals, and antioxidants, through diet or supplements, is vital for maintaining health and energy. Lifestyle decisions, including physical activity, stress management, and sleep quality, also significantly influence health. Frequent exercise improves muscular, cardiovascular, and mental health by reducing stress and anxiety. Emotional resilience and mental clarity can be achieved by incorporating stress-reduction practices like yoga, meditation, and deep breathing. Sustaining a healthy sleep pattern is essential for better general health and higher energy levels.

**Keywords:** Cardiovascular diseases, Diabetes, Lifestyle interventions, Metabolic disorders, Metabolic health, Metabolism, Nutritional interventions, Obesity.

## **INTRODUCTION**

Nutritional and lifestyle interventions are crucial in shaping humans' mental and physical health and well-being over time. Understanding overall metabolic health


---

\* **Corresponding authors Amit Aggarwal and Ankush Goyal:** Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India;  
E-mails: goyal.ankush35@gmail.com; amitaggarwal78@yahoo.co.in



considering various factors such as lifestyle interventions, metabolic responses to stress, and the impact of different oncogenes on metabolic pathways is also unnecessary. These lifestyle modifications include regular physical activity, quality sleep, and healthy eating habits (Fig. 1) [1 - 4].

Nutritional interventions aid in improving various aspects of human health across different age groups. Based on research-based studies, the diet and lifestyle choices we make have an impact on health outcomes. Research studies on nutritional interventions have shown positive outcomes [5].



**Fig. (1).** Nutritional and lifestyle interventions.

Several health problems such as immunological disorders, bone-related issues, and cognitive disorders are associated with nutritional deficiency. In addition to this, the metabolic processes are also significantly affected by nutrients. These nutrients are generally classified as micronutrients and macronutrients [6]. The effect of dietary patterns on health is a key focus. These patterns can be more useful in providing a better way to understand how diet influences metabolic health. When examining the overall impact of food and nutrients, these dietary patterns reflect real eating habits, *i.e.*, consumption of foods or meals rather than just individual dietary components. This is crucial for tailoring effective nutritional interventions to enhance metabolic health [7]. Functional foods and

supplements have also increased in this era to reduce the complex interactions between the risk factors produced by metabolic syndrome (MetS) [8].

Lifestyle interventions, including physical activity, smoking cessation, stress management, and quality sleep, significantly influence metabolic health in individuals with various conditions like metabolic syndrome, prediabetes, and Type 2 diabetes [9]. These interventions, can reduce the risk of cardiovascular diseases, and improve clinical parameters such as blood glucose level and blood pressure [3, 5, 7, 10 - 71]. Further, sleep deprivation is closely related to metabolic dysfunction. It is also responsible for the chronic misalignment of endogenous rhythms contributing to metabolic issues [72]. Engaging in physical activity is directly associated with metabolic health. Regular physical activity can improve sleep quality and manage sleep disorders like insomnia. The intensity of physical activities also affects sleep quality. High-intensity physical activities can cause difficulty sleeping, while moderate-intensity physical activities are better for quality sleep. Stress management interventions can significantly improve health outcomes in patients with metabolic syndrome and psychological symptoms, including depression, anxiety, and schizophrenia. Stress reduction techniques improve overall metabolic health [44, 73, 74]. Further, hydration (water intake) also supports metabolism through different mechanisms. Some intervention and preclinical studies point to a direct association of dehydration with metabolic dysfunction and elevated arginine vasopressin (AVP) levels, a key hormone in fluid homeostasis [75].

## **NUTRITIONAL INTERVENTIONS**

Nutritional interventions are customized approaches to manage a wide range of metabolic disorders including obesity, diabetes, heart disease, digestive problems, allergies, and deficiencies in essential nutrients [45]. These interventions are crucial in improving various aspects of human health across different age groups. Studies have shown that implementing these interventions can lead to positive outcomes such as enhanced physical development in children under 8 years old, with longer intervention periods significantly impacting weight-for-height and weight-for-age scores [76]. In physically active women aged 50 to 70 years, combining nutritional interventions with different training models resulted in enhanced physical capacities, quality of life, and level of physical activity, regardless of the type of training used [46].

Generally, macronutrients and micronutrients are classified as nutritional strategies to overcome health issues related to incomplete metabolism. Additionally, in school settings, nutritional interventions were found to potentially reduce the prevalence of overweight and obesity among students, with multi-

## Future Directions and Research Frontiers

**Sunil Dutt<sup>1</sup>, Shiwank Rana<sup>2</sup>, Satish Patnaik<sup>4</sup>, Rajesh Kumar<sup>1,\*</sup> and Ravinesh Mishra<sup>3</sup>**

<sup>1</sup> *Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India*

<sup>2</sup> *Dreamz College of Pharmacy, Sundernagar, Mandi, Himachal Pradesh, India*

<sup>3</sup> *School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences & Technology, Baddi, Solan, Himachal Pradesh, India*

<sup>4</sup> *Stein Eye Institute, Geffen School of Medicine, University of California, Los Angeles, California, USA*

**Abstract:** Incomplete biochemical pathways lead to the build-up of metabolic intermediates, which is known as incomplete metabolism. This condition is significant for many physiological and pathological processes. This chapter highlights the importance of incomplete metabolism in understanding disease mechanisms, energy generation, and cellular adaptability as it examines future directions and research horizons in the field. Determining the underlying cause of incomplete metabolism requires advances in metabolomic profiling, enzyme functioning research, and the discovery of new biomarkers. Moreover, studying incomplete metabolic pathways in relation to illnesses like diabetes, cancer, and neurological problems might lead to the creation of focused treatment plans. Understanding how cells adapt to metabolic inefficiencies, especially in the mitochondria, might help us understand how cells survive under stressful circumstances.

Furthermore, new prospects for individualized therapy are presented by the interaction between environmental factors, the gut microbiota, and incomplete metabolism. Using creative methods, this investigation expands our understanding of basic biology and creates new avenues for therapeutic treatments targeted at enhancing the prognosis of metabolic and associated disorders. Incomplete metabolism is emerging as a major area with broad implications for fundamental science and therapeutic applications, as research into it continues.

**Keywords:** Biochemical pathways, Metabolomics, Personalized medicines, Pharmacogenomics, Transcriptomics.

---

\* **Corresponding Author Rajesh Kumar:** Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India; E-mail: rajdhiman60@gmail.com

## INTRODUCTION

A person's health is directly impacted by incomplete metabolism. A compromised metabolism may increase the risk of cardiovascular disease. Both acquired and genetic factors may contribute to the pathophysiology of metabolic dysfunction. Indeed, type 2 diabetes and cardiovascular diseases are among the consequences closely associated with incomplete metabolism of blood glucose. However, poor iron and fat metabolism can lead to obesity [1, 2]. Early identification of clinical biomarkers and diagnosis can be crucial in managing negative health effects resulting from incomplete metabolism. Metabolome analysis is the technique to identify and analyze biological fluids and clinical biomarkers. In this way, we can monitor the metabolic function of a patient. We can find clinical indicators of metabolic dysfunction by combining specialized techniques like Gas and Liquid Chromatography (GC and LC) with Nuclear Magnetic Resonance (NMR) or Mass Spectroscopy (MS). For instance, upregulation of glucose, lactate, CH<sub>3</sub> lipids, and CH<sub>2</sub> lipids, and downregulation of alanine and choline in human serum, as revealed by NMR biomarker analysis, may contribute to the development of chronic illnesses like diabetes and obesity [3, 4]. Management of metabolic dysfunction requires a lifestyle change and an appropriate diet plan. Another novel strategy for treating metabolic dysfunction is gender-specific personalized nutrition and medicine, which involves tracking the composition of the microbiota, the rate of inflammation, oxidative stress, and the metabolism of fats and carbohydrates. Management of metabolic dysfunction may benefit from dietary pattern modifications that include or exclude particular foods. Omega-3, polyphenols, flavonoids, curcumin, chlorogenic acid, and pre- and probiotics may aid in the management of and protection against metabolic dysfunction when included in the diet [5 - 8].

Finally, we can say that an incomplete metabolism directly affects an individual's health because it can result in a number of chronic illnesses, including obesity, cardiovascular disease, diabetes, and more. Numerous studies on the treatment of metabolic disorders are still ongoing. Personalised medications, early biomarker detection and diagnosis, and appropriate dietary modifications are a few strategies that can be crucial in managing an incomplete metabolism.

## Pharmacogenomics and Personalized Medicine

Genetic variables impact a patient's response to medication, influencing both the toxicity and effectiveness of the treatment. Using a person's genetic information, pharmacogenomics appears to be an effective approach that can predict a sub-therapeutic response to a drug and a higher risk of adverse effects, as shown in Fig. (1).




Fig. (1). Pharmacogenomics and personalized medicine.

Genetic technologies, such as pharmacogenomics and personalized medicine, are being applied to improve patient outcomes and guide medication selection. Pharmacogenomics and personalized medicine are extensively employed in the management of metabolic illnesses and disorders resulting from dysfunction in the metabolism [9, 10]. Personalized medicines for various metabolic conditions are discussed below.

### Diabetes Mellitus

Diabetes mellitus (DM) is a condition caused by insufficient glucose metabolism in the blood. *AGTR1*, *IL6*, *NOS3*, and *TNFA* genes have been discovered to be frequently associated with various illnesses, according to a study. The *STAT3* polyautoimmunopathy, which encompasses intrauterine growth retardation, thyroid dysfunction, celiac disease, and persistent autoimmune neonatal diabetes, has been linked to mutations in the *STAT3* gene [11, 13]. An increased understanding of the need for personalized diagnosis in Type 1 diabetes has driven extensive research efforts toward the development of personalized therapies [14]. The most popular method of treating Type I diabetes is manual blood sugar testing, which is followed by several daily subcutaneous insulin injections. Conventional injections may be replaced with insulin pumps. Given

## CHAPTER 10

# Supporting Caregivers and Patients in Managing Incomplete Metabolism

Ashima Thakur<sup>2</sup>, Ashok Kumar<sup>2</sup>, Rahul Sharma<sup>3</sup>, Pooja Thakur<sup>4</sup>, Pankaj Kalia<sup>4</sup>, Rajesh Kumar<sup>4</sup> and Shilpa Chandel<sup>1,2,\*</sup>

<sup>1</sup> Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, India

<sup>2</sup> Faculty of Pharmaceutical Sciences, The ICFAI University, Baddi, Himachal Pradesh, India

<sup>3</sup> Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy Bela, Punjab, India

<sup>4</sup> Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India

**Abstract:** An effective solution that is revolutionizing the current healthcare environment focuses on empowering caregivers and patients through enhanced care delivery. The proposed plan emphasizes the active involvement of healthcare professionals (e.g., nurses, doctors, pharmacists) and patients, promoting the development of specific skills, awareness, and access to health-related resources and tools to support effective self-management. A more collaborative and holistic approach to care has replaced the traditional defensive model, giving equal importance to the role of the caregiver and the involvement of the patient in the healing process. Adult education related to health and well-being is essential for both caregivers and patients, as it transfers knowledge about diseases, their treatments, and necessary lifestyle adjustments. Various channels, including personal consultations, health and disease-related pamphlets and magazines, as well as digital health tools, such as telemedicine and mobile health applications, enable caregivers to interact with patients more effectively.

Another notable approach gaining attention today is the creation of support networks, groups of caregivers who assist patients suffering from depression and anxiety by offering emotional and physical support. These networks play a vital role in reducing suicide cases and improving the overall well-being of affected individuals. They help foster a sense of responsibility, build a resilient community, and provide a platform for caregivers to share their experiences in managing such patients. Caregivers can be empowered through rigorous healthcare-related training and should be equipped with all the essential tools needed for effective caregiving. Ultimately, by providing caregivers with the necessary skills and resources, the quality of life and well-being of

\* **Corresponding author Shilpa Chandel:** Department of Pharmacy, Banasthali Vidyapith, Banasthali, Rajasthan, India, Faculty of Pharmaceutical Sciences, The ICFAI University, Baddi, Himachal Pradesh, India; E-mail: shilpachandel65@gmail.com

both patients and caregivers can be significantly improved. Therefore, greater focus should be placed on building a patient-centric healthcare structure.

**Keywords:** Anxiety, Community, Caregivers, Depression, Healthcare, Patients, Support network.


## INTRODUCTION

In today's era, it is crucial to empower both patients and caregivers, as prioritizing health is of utmost importance. Empowering caregivers and patients involves developing the necessary skill sets, knowledge, and confidence to manage health and various medical conditions effectively [1 - 6]. Several critical aspects must be considered, such as the type of illness, and the expectations of physicians, nurses, pharmacists, and other medical professionals in delivering effective treatment.

Empowering medical professionals leads to improved health outcomes, increased patient satisfaction, and more effective use of healthcare resources [7]. Similarly, empowering patients fosters stronger alliances with caregivers, encourages treatment adherence, promotes preventive health behaviors, and enhances the overall quality of the healthcare experience. These efforts help cultivate a collaborative network among caregivers, patients, and healthcare providers, ultimately advancing a more patient-centric care model and contributing to a healthier, more resilient community.

In recent years, the healthcare system has undergone a significant transformation, especially in the relationship between patients and medical professionals [8]. In the past, an overprotective model of care excluded patients from participating in their treatment and recovery, placing full responsibility on healthcare providers. According to this paternalistic model, physicians were viewed as the sole decision-makers, assumed to know what was best for the patient. As a result, patients were often left feeling passive, disempowered, and excluded from the decision-making process. However, over time, advancements in healthcare have highlighted the limitations and shortcomings of such an approach, as illustrated in Fig. (1) [9, 10].

Paternalistic care was extremely prevalent in ancient times. Hippocrates, considered the father of modern medicine, was a native of Greece and was highly admired in both Greece and Rome. In addition to treating illnesses, he also guided people of that era on healthy eating habits [11, 12]. During the medieval period, doctors held a prestigious position closely tied to religious beliefs. As a result, they were often regarded as god-like figures or representatives of divine authority, granting them unquestioned power and sovereign knowledge [13].



**Fig. (1).** This figure illustrates that an individual's well-being depends on physical, psychological, and societal factors.

By the 19th century, the paternalistic model of care had become more orthodox and rigid. The growing number of medical institutions and professional organizations, along with advancements in the medical field, reinforced the authority of physicians. This further solidified their role as the sole decision-makers in patient care [14].

### CONDEMNATION OF PATERNALISTIC CARE MODELS

The condemnation of paternalistic care models began in the 20th century as people increasingly advocated for their societal rights [15, 16]. Numerous social movements, including feminist, civil rights, and disability rights movements, highlighted the crucial importance of personal autonomy and the right to independence. These movements not only challenged the exclusion of patients from their own care and treatment decisions but also promoted meaningful patient involvement in health-related choices [17 - 20]. Various bioethicists researching social, ethical, and legal issues in biomedicine and biomedical research argued that patients have the right to be fully informed about their treatments and medications. Furthermore, if patients disagree with their treatment plans, they should have the right to oppose a physician's decision. This shift empowered patients to express their opinions and make choices openly and confidently in collaboration with their caregivers [21 - 23].



**SUBJECT INDEX****A**

Acetyl-CoA 3, 4, 5, 8, 58, 59 64, 68, 75, 77, 104, 194  
     central metabolite 8  
     fatty acid synthesis 8, 59, 68  
 Acetylation 1, 2, 22, 24  
     histone 22, 24  
 Acidosis 4, 90, 104, 107, 191  
     lactic 4, 90, 104, 107  
 Aconitase 13, 107  
 Adipocytes 184, 211  
     being of 184, 211  
 Adipose Tissue 18, 94, 260, 263  
 Aging 56, 78, 81, 260, 262, 267, 275  
     age-related disorders 78, 81  
 Alanine 6, 7, 14, 76, 262  
 Alcohol Dehydrogenase (ADH) 3, 37  
 Aldehyde Dehydrogenase (ALDH) 4, 37, 142  
     deficiency 37, 142  
 Allosteric Regulation 1, 17, 69, 75  
     enzyme activity 17, 69, 75  
 Alpha-Ketoglutarate 5, 13, 15, 16, 77  
     dehydrogenase 13, 16, 77  
 Amino Acids 1, 5, 7, 19, 38, 58, 72, 91, 92, 100, 104, 192, 227, 253  
     catabolism 92, 104  
     essential 7, 192  
 Ammonia 58, 92, 195  
     scavengers 195  
 Anabolic Pathways 1, 58, 91  
 Anaerobic Conditions 13, 75  
 Anemia 90, 97, 148, 228  
     iron deficiency 97, 148  
 Antioxidant 76, 98, 108, 209, 230, 265  
     defence 108, 209  
 ATP (Adenosine Triphosphate) 1, 10, 12, 14, 40, 57, 64, 75, 102, 261  
     currency 1, 10  
     hydrolysis 1, 10, 12

**B**

BCAA (Branched-chain amino acids) 38, 99, 192  
 Beta-Oxidation 58, 98, 103, 107  
     mitochondrial 98, 103  
 Bioenergetics 10, 37, 40  
 Biomarkers 63, 158, 161, 253, 261, 272, 274  
     diagnostic 158, 161, 261  
     metabolic 158, 253  
 Biosynthesis 5, 8, 20, 59, 67, 78  
     fatty acid 8, 59  
 Biotransformation 3, 95, 135  
 Blood-Brain Barrier (BBB) 38, 198  
 Bone Health 97, 228

**C**

Calcium 97, 228  
 Cancer 56, 79, 90, 163, 255, 262, 275  
 Carbohydrates 19, 72, 96, 190, 192, 193, 194, 227  
     metabolism 72, 96, 193  
     metabolism disorders 190  
 Carnitine 13, 98, 190, 209  
     deficiency 190  
 Catabolic Pathways 1, 58, 91  
 Cellular Stress 41, 98, 224  
 Cholesterol 8, 72, 228  
 Chronic Diseases 41, 91, 137, 224, 229, 260, 289  
     kidney disease 137, 260  
 Citrate 5, 14, 64, 68  
 Citric Acid Cycle 3, 4, 10, 64, 73, 185  
     intermediates 73  
 Clinical Trials 163, 187  
 Cofactor Supplementation 187, 194  
 CRISPR-Cas9 110, 187, 202, 204  
 Cytochrome P450 (CYP450) 2, 93, 114, 139, 261

## ***Subject Index***

### **D**

Diabetes Mellitus (DM) 42, 91, 98, 227, 232, 254, 262, 268  
  type 2 227, 232  
Diagnostic Biomarkers 158, 161, 261  
DNA Methylation 22, 228  
Drug Accumulation 36, 90, 95, 185  
Drug Clearance 96, 137  
Drug Interactions 36, 93, 128, 132  
Drug Metabolism 1, 35, 36, 90, 95, 111, 125, 258  
  incomplete 36, 90, 111

### **E**

Electron Transport Chain (ETC) 10, 102  
Elimination 1, 95  
Endocrine Disruptors 148  
Energy Currency 1, 10  
Energy Generation 40, 102, 260  
Enzyme Deficiency 35, 90, 111, 185, 196  
Enzyme Replacement Therapy (ERT) 92, 111, 187, 196  
Epigenetic Regulation 1, 22, 252  
Ethanol Metabolism 3, 37  
F  
Fabry Disease 191, 196  
Fasting 19, 72, 210  
Fatty Acid Oxidation 90, 98, 103  
Fatty Acids 19, 68, 104  
Feedback Inhibition 1, 69  
Fiber 230  
Folate 97, 228  
Fructose 190, 193

### **G**

Galactosemia 37, 190  
Gaucher Disease 191, 196  
Gene Editing 110, 202, 204  
Gene Expression 22, 274

## ***Impact of Incomplete Metabolism on Health 305***

Gene Therapy 92, 187, 201, 255  
Genetic Factors 93, 253, 266  
Glucagon 17, 69  
Gluconeogenesis 1, 9, 74  
Glucose 17, 74, 98, 193  
Glucose-6-Phosphate (G6P) 9, 74  
Glycogen 18, 101, 190, 193, 261  
  storage diseases (GSDs) 101, 190  
Glycolysis 1, 14, 40, 64, 185  
Gout 131, 266  
GTP (Guanosine Triphosphate) 6, 64  
Gut Microbiota 237, 258

### **H**

Heavy Metals 147, 266  
Heme Synthesis 16  
Hemolytic Anemia 93  
Hereditary Fructose Intolerance (HFI) 190  
Homeostasis 12, 74, 97, 185  
Hormonal Regulation 1, 17  
Hyperammonemia 192, 195  
Hyperglycemia 101, 264  
Hyperuricemia 131, 195

### **I**

Imaging Biomarkers (IBs) 164  
Inborn Errors of Metabolism (IEMs) 40, 187  
Insulin 17, 98, 234, 264  
  resistance 98, 264  
Isocitrate 6, 79  
Isoleucine 38, 190

### **K**

Ketogenic Diets 192  
Ketone Bodies 8, 96  
Krebs Cycle 1, 64, 185  
L  
Lactate 4, 104, 262  
Lactic Acidosis 90, 104

Lactose Intolerance 128  
Leucine 38, 190  
Lipid Metabolism 90, 227  
Lipogenesis 1, 19  
Liver 3, 93, 136, 262  
Lysosomal Storage Disorders (LSDs) 191

## M

Magnesium 97, 228  
Maple Syrup Urine Disease (MSUD) 35, 91, 99, 190  
Metabolic Syndrome (MetS) 42, 228, 232, 262  
Metabolites 2, 36, 57, 90, 125, 184, 258  
  accumulation 36, 90, 184  
Metabolomics 158, 274  
Micronutrients 97, 228, 240  
Mitochondrial Dysfunction 40, 90, 102, 262  
Myopathy 90, 130

## N

NAD<sup>+</sup>/NADH 3, 64, 104, 210  
NADPH 8, 209  
Nonalcoholic Fatty Liver Disease (NAFLD) 90, 98  
Neurodegenerative Diseases 79, 172, 265  
Neurotoxicity 38, 90  
Nucleotide Biosynthesis 8  
Nutrient Availability 1, 18

## O

Obesity 91, 228, 262, 268  
Oxidative Phosphorylation 10, 64  
Oxidative Stress 98, 265  
Oxaloacetate (OAA) 4, 79

## P

Pancreas 17, 262

Parkinson's Disease (PD) 79, 172  
Pentose Phosphate Pathway (PPP) 8  
Personalized Medicine 90, 253  
Pharmacodynamics 1, 93, 258  
Pharmacogenomics 90, 253  
Pharmacological Chaperones 208  
Pharmacological Treatments 194  
Phenylalanine 38, 91, 185  
Phenylketonuria (PKU) 35, 91, 185  
Phosphorylation 1, 10  
Physical Activity 222, 232, 264  
Pivampicillin 2  
Polypharmacy 125  
Prodrugs 1, 95  
Protein Synthesis 1, 59, 227  
Proteomics 273  
Pyruvate 4, 75, 262

## R

Reactive Oxygen Species (ROS) 98, 265  
Redox Balance 108  
Reduction 2, 77, 209  
Renal Clearance 96  
Ribose-5-Phosphate 8

## S

SGLT2 Inhibitors 184  
Sedentary Lifestyle 237  
Seizures 38, 134  
Smoking 144, 224  
Stem Cell Therapy 187, 206  
Stress Management 222, 235  
Substrate Reduction Therapy (SRT) 195  
Succinyl-CoA 6, 73

## T

Tay-Sachs Disease 191  
TCA Cycle 5  
Therapeutic Drug Monitoring 96

***Subject Index***

Thiamine (Vitamin B1) 228  
Thyroid Hormone Metabolism 138  
Transformation 1  
Transcriptomics 271  
Triglycerides 19, 228  
Tyrosine 7, 185

**U**

Urea Cycle 92, 195  
Uric Acid 131, 262

**V**

Valine 38, 190  
Viral Vectors 201  
Vitamin B12 97, 130, 228  
Vitamin D 90, 228

**W**

Warfarin 133

**X**

Xenobiotic 1

***Impact of Incomplete Metabolism on Health 307***



**Rajesh Kumar**

---

Rajesh Kumar is working as an Associate Professor at the Maharaja Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh. He has worked as a Junior and Senior Research Fellow in the Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, and has strong hands-on experience in bioanalytical techniques, including sample preparation, extraction of drug molecules from biological samples, chromatographic separations, and interpretation using HPLC and GC-MS. He also has three years of experience in conducting Therapeutic Drug Monitoring (TDM) of different drug molecules.

He has published several research papers, including review articles, journal editorials, and book chapters in various peer-reviewed national and international journals. During his research career, he has received the UGC-BHU JRF Research Fellowship Award (2016–17), National Fellowship JRF & SRF (NFSC Award) 2017–18 by UGC, and the ICMR SRF Award 2018. He was also appointed as a CCSEA Nominee, Government of India (2024) and received the Young Researcher Award 2025 by I.K. Gujral Punjab Technical University, Punjab.